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Abstract 
Background: The extent and the distribution of end stage kidney disease (ESKD) in Libya 
have not been reported despite provision of dialysis over 4 decades. The aim of this thesis is to 
develop the first comprehensive description of the epidemiology of dialysis-treated ESKD in 
adults in Libya as well as to assess the outcomes of this treatment. 
Methods: A structured interview regarding dialysis provision and infection control measures 
was conducted with the medical directors of all 40 dialysis centres and 28 centres were visited. 
In the same time demographic and clinical data were obtained regarding all adult patients 
treated at all maintenance dialysis facilities in Libya from May to August 2009. Additional 
information about the patterns of vascular access used for haemodialysis (HD) as well as 
prevalence and incidence of hepatitis Band/or C infection was collected and analysed. 
Subsequently data were collected prospectively from September 2009 to August 20 I O. 
Results: There were 40 functioning maintenance dialysis centres in Libya (one of them was 
serving children only). The total number of adult patients was 2417. The prevalence rate of 
ESKD treated by dialysis was 624 per million population. Most dialysis units were located in 
the northern part of the country and only 12.5% were free standing units. Only three centres 
offered peritoneal dialysis. There were 192 HD rooms. They hosted 713 functioning HD 
stations, giving a ratio of one machine to 3.4 patients. Nephrologist/internist to patient ratio 
was 1 :40 and nurse to patient ratio was 1:3.7. There was wide variation in monitoring of 
dialysis patients with dialysis adequacy assessed only in a minority. 85% of prevalent patients 
were aged <65 years and 58% were male. The prevalence of ESKD varied considerably with 
age with a peak at 55-64 years (2475 pmp for males; 2197 pmp for females). The annual 
incidence rate was 282 pmp with some regional variation and a substantially higher rate in the 
South (617 pmp). The most common cause of ESKD among prevalent and incident patients 
was diabetes. Other important causes were glomerulonephritis, hypertensive nephropathy and 
congenital or hereditary diseases. During one year follow- up, 458 deaths occurred, (crude 
annual mortality rate of 21.2%). Of these, 3 1 % were due to ischaemic heart disease, 16% 
cerebrovascular accidents and 16% due to infection. Annual mortal ity rate was 0-70% in 
different dialysis centres. Best survival was in age group 25-34 years. Binary logistic 
regression analysis identified age at onset of dialysis, physical dependency, diabetes and 
predialysis urea as independent determinants of increased mortality. Of all dialysis- treated 
patients, 34.9% were sero-positive for HBV and/or HCV (anti-HCV positive 31.1%; HBsAg 
positive 2.6%; both positive \.2%). The prevalence of HBV±HCV infection varied widely 
between HD centres from 0% to 75.9%. Sero-positive patients were younger, had longer time 
on dialysis and more previous blood transfusions. Prospective follow-up revealed an incidence 
ofsero-conversion of7.7% during I year (7.1% HCV; 0.6% HBV). Wide variation in rates of 
newly acquired infections was observed between dialysis centres. Duration of dialysis, history 
of previous renal transplant and history of receiving HD in another centre in Libya were 
significantly associated with sero-conversion. The majority of HD- treated patients (91.9%; 
n=1573) were using permanent vascular access in the form of arteriovenous fistula or 
arteriovenous graft. Patients with permanent vascular access were more likely to be male and 
less likely to be diabetic. Most patients had commenced HD using a temporary central venous 
catheter (91.8%). Vascular access- related complications were: thrombosis (46.7%), aneurysm 
(22.6%), infection (11.5%) and haemorrhage (10.2%). Hospitalisation for VA related 
complications was reported by 31.4%. 
Conclusion: ESKD in Libya is a major health problem where the incidence rate is among the 
highest in the world. Despite rapid expansion of dialysis services throughout the country, this 
thesis has identified that many aspects of dialysis provision are suboptimal and that outcomes 
are relatively poor. We have identified several major challenges to improving the quality of 
dialysis provision including lack of dialysis practice guidelines, absence of auditing and quality 
control and limited access to kidney transplantation. As Libya reorganises its health services in 
the post-conflict period it is hoped that this study will be the first step in establishing a renal 
registry and that the areas of concern highlighted will prompt the implementation of national 
clinical practice guidelines for dialysis. 
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Chapter 1 
Introduction 
1. Introduction 
1.1. End-Stage Kidney Disease 
End-stage kidney disease (ESKD) refers operationally to the advanced and irreversible loss of 
kidney function which necessities treatment with maintenance dialysis (haemodialysis (HD) or 
peritoneal dialysis (PD» or kidney transplantation. Scientifically, it is defined as the failure or 
near failure of the kidneys to perform their normal functions, which include excretion of 
metabolites, maintenance of acid-base status, fluid and electrolyte balance and the synthesis of 
hormones such as erythropoietin and rennin (I, 2). ESKD is usually the end result of a 
progressive Chronic Kidney Disease (CKD) and gradual loss of renal function. Occasionally, it 
is the result of a rapidly progressive disease of sudden onset. Few symptoms develop until 
more than 75% of glomerular filtration is lost. Symptoms worsen as kidney function decreases 
beyond this level. If the condition continues unchecked, uremic toxins accumulate and produce 
potentially fatal physiologic changes in all major organ systems. 
The term ESKD corresponds with CKD stage 5. The Kidney Disease Outcomes Quality 
Initiative (KDOQI) of the National Kidney Foundation (NKF) in the United States provided 
evidence-based clinical practice guidelines for all stages of CKD and related complications in 
2002. ESKD is defined as glomerular filtration rate (GFR) of less than 15 ml/min/l.73m 2 body 
surface area, irrespective of the underlying aetiology of the kidney damage (I). 
The GFR is considered the best measure of overall kidney function (3, 4). Normal GFR varies 
according to age, sex and body size. In young adults, the normal GFR is approximately 120 to 
130 mL per minute per 1.73 m2 and declines with age (I, 4). The NKF/KDOQI working group 
defined CKD in adults as: 
• Kidney damage for 2:3 months, as defined by structural or functional abnormalities of the 
kidney, with or without decreased GFR, manifest by either pathological abnormalities, or 
markers of kidney damage, including abnormalities in the composition of blood, urine or 
imaging tests. Or 
• Decreased GFR, with or without evidence of kidney damage. 
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CKD is further subdivided into five subgroups according to the degree of severity of estimated 
GFR reduction as described in table I. I. 
Table 1. 1: Stages of Chronic Kidney Diseases 
Glomerular filtration rate 
(mLimin/1.73 m2) 
2:90 
60-89 
30-59 
15-29 
< 15 
Stages 
2 
3 
4 
5 
Description 
Kidney damage with normal or jGFR 
Kidney damage with mild ~ G F R R
Moderate ~ G F R R
Severe ~ G F R R
End-Stage Kidney Disease (ESKD) 
1.2. Global trends in end-stage kidney disease 
The number of patients with ESKD is increasing worldwide as a consequence of the rise in 
non-communicable diseases. ESKD is a life-long medical condition with profound impact on 
patients, families and the health care sector. The World Health Report 2002 and Global Burden 
of Disease project indicated that diseases of the kidney and urinary tract significantly 
contribute to the global burden of diseases (http://www.who.int/whr/2002/en/). Recently it was 
estimated that globally over 2 million people require treatment for ESKD to sustain life (5). In 
reality the number might be 10 fold higher than the estimated figures as the access to renal 
replacement therapy (RRT) is restricted or not available in over 112 countries and many 
patients die before having access to diagnostic and therapeutic health services (6-9). 
Consequently, it has been estimated that worldwide more than a million people die every year 
from ESKD. Moreover, management of ESKD is a major cost pressure even in countries that 
2 
can afford it. These factors render ESKD an important focus of health care planning even in the 
developed world, but the problems they delineate in the developing world are far more 
challenging (7). 
Trends in ESKD are best studied longitudinally from annual renal registry reports. They 
provide the best tool for assessing the overall epidemiology of renal diseases in a community 
and permit international comparison. Renal registries are not established in many countries, 
where the trends are studied using other observational methods. However, interpreting rates of 
incidence and prevalence of ESKD across countries is complicated by the lack of uniform data 
collection methods. 
According to the 20 II report of the United States Renal Data System (USRDS) (10), the rates 
of incident ESKD across the globe show important trends; rates have slowed in some countries, 
while rising or remaining stable in others. The United States, Taiwan and Japan continue to 
have some of the highest rates, at 355 per million population (pmp), 347 pmp and 287 pmp in 
2009 (figure 1.1). 
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Figure 1. 1: Incidence of ESKD in different countries, 2009- United States Renal 
Data System (2011) 
The annual incidence of ESKD in the United States showed relative stability as compared to 
data from 2000-2009 (10). This secular trend is quite different from that observed in the 1980s 
and 1990s during which the incidence of ESKD increased at a rapid rate (10). The annual 
report of the European Renal Association-European Dialysis and Transplant Association 
Registry (ERA-EDT A) 2009 (II), which gathers data from many European national registries, 
showed an overall incidence rate of ESKD among all registries of 122 pmp. It also showed 
4 
wide variation in the incidence rates reported by different countries. During 2008, the highest 
incidence rates were reported by Turkey (264 pmp), Portugal (232 pmp) and Greece (199 
pmp), whereas incidence rates below 100 pmp were reported by Ukraine (15 pmp), 
Montenegro (30 pmp), Russia (37 pmp), Estonia (66 pmp), Iceland (73 pmp), Latvia (95 pmp), 
Finland (95 pmp) and Romania (96 pmp) (II). Similarly, evaluation of trends from 2004 to 
2008 showed minor increases in most countries and levelling off of rates or even a slight 
decrease in incidence of ESKD. The Thirteenth Annua l Report of The UK Renal Registry 
showed that the incidence rate in the UK during 2009 was stable at 109 pmp and, simi larly 
rates had leve lled off in the last three years ( 12) (figure 1. 2). 
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Figure 1. 2: Incidence rates of renal replacement therapy in the countries of the 
United Kingdom 1990- 2009 
Similarly, The Thirty Third Report of the Australia and New Zealand Dialysis and Transplant 
Registry (2010) (13) showed that the incidence of ESKD in Australia was 107 pmp in 2009, a 
decrease of 8% from 2008 (119 pmp) when the incidence rate was similar to 2005 (113 pmp). 
Therefore, most recent reports from developed countries show no change or a small decrease in 
the rate of new cases. In these countries, success may be attributed to app lication of preventive 
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measures including control of blood pressure, better glycemic control and screening of at risk 
population (14). 
Incidence rates reported from the Middle and Far East show variable patterns. The Malaysian 
Dialysis and Transplant Registry (15) reported an incidence of ESKD treated with dialysis of 
170 pmp in 2009 which is approximately as double the rate during 2001 (88 pmp). Reports 
from other countries in the region depended on small studies rather than well-established renal 
registries. For instance, the incidence in Qatar was 202 pmp (16), Tunisia (159 pmp) (17), 
Bhopal city in India (151 pmp) (18), Saudi Arabia (122 pmp) (19), Jordan (Ill pmp) (20) and 
Aleppo city in Syria (60 pmp) (21). However, the long term trend of ESKD incidence in most 
Middle and Far East countries could not be interpreted in these places due to insufficient 
information. 
The incidence of ESKD varies in demographic subgroups of different populations. Male 
predominance in incident cases has been reported by many registries. According to the 20 II 
USRDS report (10), the incidence rate in males was 353 pmp while it was 222 pmp for 
females. Data from the ERA-EDTA Registry (II) showed that incident males outnumbered 
females in all countries reporting to the registry during 2008, with wide differences between 
genders in some countries where male incidence rate was almost double the rate in females. 
For example, in Greece, incidence in males was 262 pmp and in females was 147 pmp (I I). 
Similarly in Finland incidence in males was III pmp and in females was 55 pmp (11). The 
Thirteenth Annual Report of The UK Renal Registry (12) showed that 61.7% of the 2009 
incident cohort was male. 
Age is another demographic variable which significantly impacts the incidence of ESKD. The 
mean age of incident patients with ESKD in developed countries is higher than those in 
developing nations. According to the 2011 USRDS report (10), the mean age of incident 
ESKD patients was 62.6 years. Incidence rates increased progressively with increasing age of 
patients such that it was 131 pmp in those aged 20-44 years and 610 pmp in those aged 45-64 
while it reached 1,407 pmp in those aged 65-74years (10) (figure I. 3). 
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Figure 1. 3: Incident counts and adjusted rates of ESKD, by age, United States 
Renal Data System (2011) 
Data from the ERA-EDT A Registry ( II ) shows that the mean age of incident patients in 2008 
ranged from 44 years in Ukraine to 69 years in Dutch-speaking Belgium. In the UK, the 
median age was 64.8 years for all incident patients and 57.1 years for non-Whites (12). In 
Australia, the mean age of incident ESKD patients was 60.7 years and the median was 63.4 
years (13). In contrast, the mean age of incident patients in the developing world is generally 
substantially lower. For instance, the mean age of incident ESKD patients during 2005 in India 
was 46 years (22). This is likely due to multiple factors including lower population life 
expectancy, rationing of RRT to younger patients and higher prevalence of kidney diseases that 
affect younger people. 
The incidence of ESKD also varies greatly across patient ethnic subgroups. According to the 
USRDS (10), the incidence in White Americans was 277 pmp, African Americans 976 pmp, 
Native Americans 523 pmp and Asian Americans 403 pmp. The incident rates in the African 
American and Native American populations were 3.5 and 1.9 times greater, respectively, than 
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the rate among whites and the rate in the Hispanic population was 1.5 times higher than that of 
non-Hispanics (10). 
Likewise, the number of patients affected by ESKD and living on RRT shows wide variation 
between countries. The prevalence of ESKD does not necessarily reflect the health status 
among communities because it depends not only on the number of new cases but also on the 
rate of survival of existing patients. It may reflect different priorities for health care and 
inadequacy of resources allocated to RRT as well as the access to renal transplantation. 
The (2011) USRDS report also showed high prevalence of ESKD in the United States with 
major racial differences. Overall, the rate of prevalent ESKD cases reached 1,738 pmp in 2009 
(10). There was an increase of 2.1 % from 2008, consistent with a similar rise per year since 
2002 (10). Point prevalence of dialysis patients was 1,210 pmp. The mean age of prevalent 
ESKD patients in the United States was 61.1 years. Prevalence rate in White Americans was 
1,279 pmp, African Americans 5,284 pmp, Native Americans 2,735 pmp and Asian Americans 
2,101 pmp (10). 
International data reported from different registries in the world showed that Taiwan and Japan 
continue to report the highest rates of prevalent ESKD, at 2,447 and 2,205 pmp, respectively, 
in 2009 (10). High prevalence rates were also reported by Jalisco (Mexico) and French-
speaking as well as Dutch-speaking Belgium, at 1,314 pmp, 1,193 pmp and 1,141 pmp, 
respectively (10). The lowest rates were reported by Bangladesh and the Philippines, at 140 
pmp and 110 pmp (10). 
The overall prevalence among all registries reporting to the ERA-EDT A Registry in 2008 was 
644 pmp (11). The highest prevalence was in Portugal (1408 pmp), Belgium (French-speaking) 
(1153 pmp) and Spain (Catalonia) (1124 pmp). The lowest prevalence was reported by Ukraine 
(89 pmp) and Russia (165 pmp). The Thirteenth Annual Report of The UK Renal Registry (23) 
showed that the prevalence rate of ESKD was 417 pmp and the median age of prevalent 
patients was 57.7 years. There were a gradual growth in the prevalence of dialysis population 
by 3.5 pmp between 2005 and 2009. It also showed that prevalence rates in males exceeded 
those in females; the peak for males was in the 75-79 year age group at 2,632 pmp and for 
females the peak was in the 70-74 year age group at 1,445 pmp (23). The prevalence rate of 
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dialysis in Australia had showed almost similar rate (473 pmp) (13). New Zealand showed 
higher prevalence rate of dialysis (524 pmp) (13) while in Malaysia it was 762 pmp (15). 
The prevalence rates for the Mediterranean region were estimated to range between 312 to 352 
pmp (24, 25). Other reports from individual countries in the region showed variable 
prevalences including Saudi Arabia (475 pmp) (19), EI-Minia city in Egypt (208 pmp) (26), 
Kuwait (240 pmp) (24) and Oman (220 pmp) (24). 
1.3. Aetiology of end-stage kidney disease 
Kidney damage may result from a multitude of primary kidney disorders or systemic diseases. 
Some factors play a role in initiating the disease in individuals and other factors drive the 
progression of the condition among those with established CKD. If the cause of CKD is not 
determined relatively early in its course the primary diagnosis may be difficult to discern. 
Generally, causes of ESKD in a population are influenced by the effect of demographic 
variables including gender, ethnicity and socioeconomic status. 
Diabetes and hypertension account together for almost 60% of ESKD (10). Diabetic 
nephropathy is rapidly becoming the single most common cause for ESKD worldwide as the 
prevalence of diabetes is increasing progressively in most countries. Over the past 25 years, the 
prevalence of type 2 diabetes has almost doubled in the United States, increased three- to five 
fold in India, Indonesia, China, Korea and Thailand (27, 28). Diabetes is extremely frequent in 
the Middle East countries. The International Diabetes Federation 
(http://www.idf.orgidiabetesatJas/) ranked Kuwait, Lebanon, Qatar, Saudi Arabia, Bahrain and 
the United Arab Emirates among the countries with highest prevalence of diabetes in the 
world. Several studies have shown that diabetes is associated with a substantially increased risk 
of ESKD (29-32). Researchers estimated that almost 40% of diabetic patients will develop 
CKD within 10 years of diagnosis (33, 34). 
Data from the USRDS (2011) (10) shows that diabetes was the primary diagnosis in 44% of 
new ESKD patients (figure I. 4) and 39% to 53% of prevalent patients in 2009. The incidence 
rate ofESKD caused by diabetes remains high in the United States, reaching 647 pmp in 2009. 
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Figure 1. 4: Incident counts and adjusted rates of ESKD, by primary diagnosis, 
United States Renal Data System (2011) 
International figures reported by the USRDS (2011) (10), showed that diabetes was the 
primary cause ofESKD in 58-60% of new patients in Malaysia, Morelos (Mexico) and Jalisco 
(Mexico). It also showed that Thailand, New Zealand, Hong Kong, the Republic of Korea, 
Japan, Taiwan and the Philippines all have rates of ESKD incidence due to diabetes of greater 
than 40%. In contrast the report showed that incidence of ESKD due to diabetes was below 
20% in Iceland, Romania, Ukraine, Montenegro, Russia, Estonia and Latvia. The ERA-EDT A 
Registry (11) showed a lower frequency of diabetes as the primary disease causing ESKD 
(20% or less) in Norway, Iceland, Russia, the Netherlands and Romania. 
The UK Renal Registry report (12) showed that diabetic nephropathy was the most common 
specific renal diagnosis causing ESKD in both the under and over 65 year age groups, 
accounting for 25% of all incident diagnoses. The Australia and New Zealand Dialysis and 
Transplant Registry (13) showed that in Australia, diabetic nephropathy was the primary cause 
for ESKD in 33% of new patients, while in New Zealand, diabetic nephropathy was the 
primary disease in 47%. Several reports from Middle East countries including Syria, Jordan, 
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Lebanon, Turkey and Iran showed that diabetes was the most frequent cause of ESKD in these 
countries (20-40%) (20,21,24,35,36). 
Other causes of ESKD include hypertension, glomerulonephritis and interstitial nephritis. 
Numerous population- based studies showed that hypertension increases the risk of ESKD (29, 
37-39). Raised systolic blood pressure was an independent risk factor for development of renal 
impairment among patients with type II diabetes (40). Furthermore, several studies have found 
a close association between the level of blood pressure and the magnitude of increased risk 
such that even modest elevations in blood pressure, are associated with increased risk of ESKD 
(29, 37, 41). Hypertension is projected to increase sharply over the next few decades, 
particularly in developing nations (42). Data from the USRDS (2011) (10) showed that 
hypertension was the primary diagnosis in 28% of new ESKD patients and the rate of ESKD 
due to hypertension has grown 8.7% from 2000- 2009, to 101 pmp. The incidence of 
glomerulonephritis has remained relatively stable in many countries. However, the contribution 
of glomerulonephritis to all causes of ESKD has declined due to increase in other causes such 
as diabetes and hypertension. Glomerulonephritis as a primary diagnosis has fallen to 23.8% in 
the United States (10). In the UK, glomerulonephritis accounted for 11.5% of all incident 
diagnoses while hypertension was the primary diagnosis in 6.9%. In Australia, 
glomerulonephritis caused 24% of cases and hypertension was the primary disease in 14% 
(13). Higher proportions of glomerulonephritis were reported from China (35%), Kuwait 
(35%) (43, 44), Costa Rica (30%) (45) and Yemen (25%) (46) whereas lower proportions were 
observed in Qatar (13%) (16), Sri-lanka (12%) (47) and Pakistan (10%) (48). Accurate 
diagnosis of glomerulonephritis requires clinicians with competence to perform a renal biopsy 
as well as pathology services for processing of the specimens and adequately trained 
pathologists. These resources remain deficient in many countries and therefore many cases of 
glomerulonephritis are probably not detected. 
Congenital and hereditary kidney diseases such as autosomal dominant polycystic kidney 
disease, Alport's disease, Fabry's disease and congenital nephrotic syndrome may cause ESKD 
at any age. The proportion of ESKD caused by congenital and hereditary kidney diseases is 
relatively small but complex genetic factors likely increase the risk of ESKD in a much larger 
proportion of populations. Among 25,883 incident ESKD patients, 22.8% reported a family 
11 
history of ESKD (49) and screening of the relatives of ESKD patients revealed evidence of 
CKD in 49.3% (50). The impact of ESKD caused by congenital and hereditary kidney diseases 
is more prominent in communities with high rates of consanguinity such as Middle East 
countries (51, 52). Furthermore, populations with a high rate of consanguinity have an 
increased prevalence of adult diseases that are associated with renal insufficiency, such as 
hypertension, metabolic syndrome and diabetes (51, 53). 
Other factors that may also cause ESKD include urinary tract disorders, chronic pyelonephritis 
and autoimmune diseases such as lupus nephritis. Obesity may directly cause glomerulopathy 
or provoke glomerular hypertension and hyperfiltration that may contribute to progression to 
ESKD (54-56). 
Despite advances in diagnostic technologies that have facilitated accurate diagnosis of the 
cause of ESKD in the majority of patients, the aetiology of ESKD remains uncertain in a 
substantial proportion of patients, even in developed countries with adequate diagnostic 
facilities. This is in part due to the fact that CKD still goes undetected in many people until it is 
advanced, making diagnosis more difficult. In developing countries, lack of diagnostic 
facilities is an important contributory factor. 
1.4. Management of patients with end-stage kidney disease 
In advanced CKD the rate of deterioration of patients' condition and tolerance to reduced GFR 
show substantial variation. The optimal timing of dialysis initiation remains uncertain but there 
is general consensus that the onset of serious symptoms and complications of uraemia 
including hyperkalaemia, metabolic acidosis, anorexia, nausea, puritis, malaise and fluid 
overload is a firm indication to commence dialysis (I). 
Detecting patients at early stages of CKD and providing proper management slows the 
progression of the disease and allows a chance for patients and families to be informed about 
RRT choices. It also creates the opportunity for pre-emptive kidney transplant. Early diagnosis 
increases the compliance of patients, builds up confidence between patients and health care 
providers, assists patients and families in coping with the psychological impact of the disease 
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and maximises chances for rehabilitation (57, 58). Furthermore, if management with dialysis is 
the agreed plan, there will be sufficient time to create suitable vascular access which improves 
outcomes on dialysis (59, 60). Conversely, late referral and an unplanned start to dialysis are 
associated with increased morbidity (61) and reduction in patient survival that persists for at 
least the first three years (62). Figure I. 5, demonstrates the relationship between late referral 
and dialysis survival such that patients referred less than 12 months before dialysis initiation 
had a significantly increased risk of death (62). 
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Figure 1. 5: Relation between time of referral before dialysis initiation and 
subsequent risk of death (Kessler et al. AJKD, 2003) 
All clinical guidelines now advocate identifYing people at risk of ESKD at an early stage and 
timely referral to nephrology care to achieve benefits of a planned start. Early referral to a 
nephrologist, despite being seemingly feasible, is often not achieved. Reports from many 
countries show that considerable proportions of patients present at late stage and need urgent 
commencement of dialysis. The USRDS (20 II) report (10) showed that more than 43% of 
ESKD patients starting therapy in 2009 had not seen a nephrologist prior to initiation. 
Similarly, The Australia and New Zealand Dialysis and Transplant Registry (13) showed that, 
during 2009, 21 % of all new patients in Australia and 17% of new patients in New Zealand 
were referred to nephrology care in less than three months before first treatment. 
Psychosocial support is important for patients, because dialysis makes them socially and 
emotionally vulnerable (63, 64). It often results in a loss of freedom, dependence on caregivers, 
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disruption of family life and reduced or loss of financial income. It also interrupts work, school 
and leisure activities, creates anger, frustration and tension and alters body image because of 
reduced physical energy (65, 66). Moreover, it causes loss or change in sexual function (67, 
68) and changes the body's appearance due to access surgery, dialysis catheter placement, 
needle marks, bone disease, or other physical deterioration (69-71). Furthermore, dialysis only 
partially replicates the removal of fluid and uraemic toxins by the kidneys and does not replace 
any of its hormonal functions. Patients are given other treatments to correct the endocrine 
deficiencies. 
1.5. Renal Replacement Therapy 
The main types of RRT are dialysis and renal transplantation. Dialysis is a process in which an 
artificial kidney or the patient's own peritoneal membrane is used to remove waste metabolites 
and maintain homeostasis. Kidney transplantation is the gold standard treatment for ESKD 
where a new kidney replaces the function of failing kidneys, but a shortage of both live and 
cadaveric donated organs leaves many people with kidney failure obligated to undergo lifelong 
dialysis. The two dialysis techniques currently available are HD and PD. 
1.5.1. Haemodialysis 
HD is performed by circulating blood through a disposable dialyzer. This is composed of 
hollow fibres of a selectively permeable material, giving a large total surface area (1-2 m2). 
Dialysate is produced by the combination of concentrate with ultrapure water 
(microbiologically pure, low endotoxin concentration and depleted in minerals). The dialysis 
fluid flows around the hollow fibres in the opposite direction to blood. It contains a low 
concentration of factors to be removed and a higher concentration of bicarbonate, allowing 
diffusion into the blood and correction of acidosis. Removal of accumulated fluid is achieved 
by applying a pressure gradient across the dialysis membrane, resulting in controlled 
ultrafiltration. Figure I. 6, illustrates a HD machine. 
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Conventionally, heparin is used to prevent clotting . HD treatment is performed three times a 
week, for 3-5 h per session. This results in adequate control of biochemistry (though not 
normalized), fluid overload, ac idosis and uraemic symptoms in most patients. 
1.5.1.1. Development of haemodialysis 
The enormous advances in medical technology during the past century laid the fo undation for 
the deve lopment of dialysis to replace kidney function. The basic theory of dialysis was first 
described by Thomas Graham in 1854, a chemist at Glasgow University (72) . He described the 
principles of the semi-permeable membrane and gave the name 'dialys is' to refer to the process 
of selective diffusion (72, 73). Graham realized that, for successful treatment of renal failure, 
toxins, which accumulate in renal fa ilure, would have to be removed. It would be necessary to 
understand the production rate of these tox ins and the rate at which they can cross the 
membrane (73). The main cornerstone in HD was laid by Abel, Rowntree and Turner in 19 14 
when they dev ised an apparatus for blood dialysis and tested the first efficient dialysis system 
on animals at Johns Hopkins University School of Medicine (74). The first human HD was 
performed in a uremic patient by Haas in 1924 at the University of Giessen in Germany (75, 
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76). He used a tubular device made of collodion and cannulated the radial and carotid 
arteries. Later that year he added a blood pump. In 1937, the first flat HD membrane made of 
cellophane was produced (77). This invention was followed by significant improvement in 
dialysers and membrane designs in 1940's by Kolff (78). 
Although HD technology continued to develop, the technique of obtaining vascular access did 
not evolve at the same rate. Repeated cannulation was not effective and was prone to 
complications. A breakthrough in vascular access came in 1960 with the introduction of the 
Quinton and Scribner arteriovenous shunt (79). This used silastic tubes fitted with Teflon tips 
as an arteriovenous shunt. Dr. Scribner's work and improvement in this field led to the 
establishment of the first outpatient dialysis centre in Seattle in the United States. Further 
significant advance in vascular access occurred in the 1960's when Cimino and Brescia first 
described their native arteriovenous fistula (A VF) for chronic vascular access (80). 
Further technological developments led to important improvements in management of blood 
leaks in the dialysers and lines and the bacterial contamination of the dialysis fluid. Also, 
production of a commercially viable dialysis solution that contained bicarbonate as a buffer led 
to reduced hypotension, headaches and hypoxia caused by acetate diaysate (81). 
1.5.1.2. Vascular access 
Long-term treatment of ESKD with HD is critically dependent on the establishment and 
maintenance of adequate vascular access. The A VF is regarded as the optimal vascular access 
in HD patients due to the better patency rates, ability to withstand repetitive needle puncture 
and association with low patient morbidity and mortality (82-84). An AVF is established by 
surgical anastamosis of an artery to a vein, forming a high flow, low resistance system. Over a 
period of 2-3 months the vein enlarges, allowing successful, repetitive venepuncture for HD. 
Forearm A VF are preferred because of accessibility and less ischemia risks of distal limb in 
comparison with proximal fistulas (85-87). Patient survival is better when an A VF is used for 
the first HD treatment compared to starting HD with a catheter and then subsequently using an 
A VF (84, 88-90). Gender differences in site and patency rates of definitive vascular access 
have been reported by numerous studies and many have observed that females are less likely 
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than males to have their permanent vascular access placed in the forearm because they have 
smaller calibre vessels (91, 92). 
Other vascular access options include arteriovenous grafts (A VG), central venous catheters 
(CVC) and tunnelled catheters. Grafts are used as an alternative when A VF formation is not 
technically possible. Instead, connection between an artery and a vein is created using a piece 
of synthetic material such as polytetrafluoroethylene or biological material (biograft). 
Temporary CVC are used when no alternative access is available. Tunnelled CVCs are 
designed to be used for longer periods when permanent vascular access cannot be achieved or 
is delayed. Several clinical guidelines and strategic plans addressing vascular access have been 
developed to improve practice in this field. The updated NKF/KDOQI goal for vascular access 
use strongly recommended A VF as the vascular access of first choice for HD and A VGs as 
second line; the use ofCVCs to be kept to a minimum (93). 
1.5.1.3. Advances in haemodialysis technology 
To improve the quality of care for dialysis patients and increase the efficiency of the process, 
various modifications of the HD technique have been developed. Advances include dialyzer 
design and high flux membranes, volumetric control and monitoring systems that provide 
online clearances. Additionally, convective clearance modalities such as hemofiltration and 
hemodiafiltration confer benefit in terms of stability on dialysis and greater clearance of some 
of the larger uraemic toxins (94). Other technical areas include dialysate buffer, electrolyte 
concentration and temperature, prescription monitoring, volume-ultrafiltration control, 
information system interface, arteriovenous access monitoring, water treatment and nocturnal 
dialysis. Currently researchers are developing a wearable device to perform HD (95). 
There is also a resurgence of interest in home HD, with improvements in water-treatment and 
machine portability and the increasing realization that with daily overnight dialysis, or daily 
short-session dialysis, there can be significant improvements in anaemia, calcium-phosphate 
balance, acidosis, nutrition, blood pressure, lipid profiles and left ventricular hypertrophy 
compared to 'standard' thrice weekly four-hour sessions (96-99). It is likely that the escalating 
numbers of patients on treatment with increasing co-morbidity load will require continued 
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refinement of dialysis techniques, whilst not replacing the need for early identification of CKO 
and assiduous mental and physical preparation in the pre- dialysis period. 
1.5.2. Peritoneal dialysis 
This technique involves using the peritoneum as a dialysis membrane. Pre-packaged fluid is 
instilled into the peritoneal space via a permanent silicone Tenckhoff catheter. It is allowed to 
dwell for a period of time (4 hours for continuous ambulatory PO). Waste products to be 
removed diffuse from the blood into the fluid. Again, the dialysis fluid contains factors that do 
not need to be removed at similar concentrations to normal plasma (calcium, magnesium and 
sodium). Acidosis is corrected by the diffusion of buffer from the fluid into the blood and 
ultrafiltration occurs down an osmotic gradient. This is produced by the fluid having a higher 
osmolality than plasma (due to a high concentration of glucose or glucose polymer within the 
dialysis fluid). Rapid drainage relies on good tube placement and function. The most common 
cause of failure is constipation with tube displacement, or inspissation of omental fat into the 
catheter's mUltiple distal perforations. PO patients characteristically are prescribed aperients to 
promote two soft bowel motions per day. The main limitations of PO relate to the development 
of peritonitis, resulting either from an infection of the exit site or contamination due to poor 
technique. There are a number of variants of the PD method. CAPD involves 3-5 exchanges of 
fluid per day, every day. The patient performs these manually, with the bag being disconnected 
between each exchange. In some patients, PO treatment is performed at night using automated 
PO either because more intensive dialysis is needed or for social reasons (100). 
1.5.3. Choice of dialysis modality 
Although there may be overriding medical or social imperatives in some cases, the choice 
between PO and HO (either unit or home based) should generally be free and not constrained 
by either clinicians prejudice or resource issues. Sufficient time and information must be 
provided to allow patients and families to make a choice. Poor or compelled choice will result 
in a higher chance of treatment failure and poorer long-term outcomes. 
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1.5.4. Provision of dialysis 
Dialysis is a life- saving measure for patients with ESKD. Currently, over 2 million people 
require RRT to sustain life worldwide (5, 101, 102) but the number in need of dialysis is 
increasing globally. The incidence and prevalence of patients with ESKD in the United States 
expected to increase by 44% and 85%, respectively, rrom 2000 to 2015 {I 03). In many 
developed countries the high cost of dialysis is partially or completely covered by government 
funds. However, over 100 countries in the developing world fail to provide an open access to 
dialysis therapy due to economic constraints (6, 7). Actually, treatment of ESKD is a low 
priority for public hospitals in many poor countries resulting in the estimated death of over I 
million people annually rrom untreated kidney failure (6, 7). For instance, in India and 
Pakistan, less than 10% of all patients with ESKD receive any kind of RRT (104, 105). 
As the need for dialysis services is escalating, many dialysis units run to full capacity and the 
need to expand the services is a serious challenge facing health care authorities. The annual 
growth of dialysis programmes ranged between 6% and 12% over the past two decades and is 
continuing to grow, particularly in developing countries {I 06). Capacity expansion requires 
new dialysis facilities but also training and recruitment of adequate staff. Capacity planning 
requires accurate knowledge of current and predicted number of patients. Other important 
services directly related to dialysis provision include pharmacy, laboratory services, technical 
support to maintain and repair dialysis machines, monitoring of water quality and surgical 
services for creation of permanent vascular access or insertion of PO catheters. 
Provision of dialysis in a country may be improved by the establishment of a Renal Registry to 
compile national data, audit service capacity and quality and provide feedback to individual 
units. 
In the last few years, growing interest and attention have been paid to the quality of health care 
services generally and to the delivery of dialysis therapy in particular. The development and 
implementation of clinical practice guidelines is one way to promote best practice and improve 
quality. Comprehensive care offered by a multidisciplinary team (that includes; nephrologists, 
dialysis nurses, renal technicians, dieticians, pharmacists, psychiatrists, surgeons, social 
workers, counsellors and occupational therapists) is needed to achieve favourable outcomes. 
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Of concern is the observation that persons with ESKD are reported to have a lower quality of 
life than persons with other chronic illnesses (107) and that quality of life is correlated with 
hospitalisation and death in persons with ESKD (108). A low quality of life associated with 
dialysis may be related to physical complications common in ESKD, such as fatigue, joint pain 
and anorexia. Low quality of life may also be due to general health perception, socioeconomic 
status, marital problems, time spent on HD, comorbidities associated with renal failure, side 
effects of multiple invasive procedures, adverse reactions to drug therapies and uncertainty 
about the future (109). A unique stressor in the population with ESKD that is not shared by 
others with different chronic diseases is the need for vascular access. Many patients worry 
about the integrity of the vascular access, fear it being damaged and view it as an embarrassing 
disfigurement (109). 
1.5.5. Monitoring of patients receiving dialysis 
The aim of long-term dialysis therapy is to replicate as far as possible the normal function of 
the kidney(s). Patients are monitored, usually monthly, for a wide range of indices relating to 
solute clearance, mineral metabolism, volume status, nutrition and anaemia. Clearance of urea 
is measured by blood sampling before and after HD, or with a combination of blood samples 
and samples of waste fluid in PD. Failure to reach certain thresholds is associated with 
increasing symptoms and increased mortality. Other laboratory investigations indicated to 
monitor dialysis patients include haemoglobin concentration and haematocrit as well as serum 
calcium, phosphorus, albumin and parathyroid hormone. 
1.5.6. Adverse effects of dialysis 
Long-term dialysis treatment impacts on multiple body systems since the kidneys are 
responsible for a wide variety of physiologic processes including clearance of metabolic waste 
products, maintain acid-base balance, regulation of sodium and potassium excretion, regulation 
of extracellular fluid volume and blood pressure as well as hormone production. The extent of 
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complications experienced by patients on dialysis may be enhanced by interaction between 
ESKD and coexisting conditions like diabetes, obesity and aging. 
1.5.6.1. Uraemia 
Patients on long term dialysis suffer from several complications attributed to the effect of 
uraemia which cannot be completely reversed because of the short and intermittent nature of 
dialysis. Uraemia causes fatigue, loss of concentration, sleep disturbances, restless legs, 
peripheral neuropathy, platelet dysfunction, anorexia, nausea, itching and cramps. 
Nevertheless, the effect of uraemia may be minimised by optimal delivery of an adequate dose 
of dialysis. 
1.5.6.2. Cardiovascular system 
Cardiovascular disease is the dominant cause of death in patients on dialysis. Several structural 
and functional peripheral vascular and cardiac abnormalities contribute to cardiovascular 
disease including left ventricular hypertrophy, reduced coronary blood flow, impaired 
microcirculation, reduced peripheral arterial compliance, arterial calcification and myocardial 
ischemia (I 10). The complex interaction between retained metabolites, inflammation, 
oxidative stress, malnutrition and the impact of recurrent volume overload with rapid fluid 
shifts that occur on dialysis ultimately leads to cardiomyopathy, cardiac failure and death (III, 
112). 
1.5.6.3. Hormone deficiency 
While dialysis partially replaces glomerular filtration, patients on dialysis still suffer from 
hormone deficiencies including calcitriol and erythropoietin. Hyperphosphataemia and low 
calcitriol levels provoke secondary hyperparathyroidism. In addition to effects on bone 
metabolism, the elevated calcium- phosphorus product associated with secondary 
hyperparathyroidism may cause arterial calcification that contributes to arterial stiffness and 
cardiovascular disease. 
Erythropoietin is the other hormone that is uniquely synthesised by the kidneys. It is 
responsible for activation of bone marrow erythroid precursors. However, the anaemia 
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commonly occurs in ESKD is usually caused by a combination of factors that include 
erythropoietin hormone deficiency, functional iron insufficiency and chronic inflammation 
(113). Other factors include, shortened red blood cell survival, blood loss related to HD and 
uremic inhibitors of erythrocyte production. 
1.5.6.4. Nutritional disturbances 
Both ESKD and dialysis have effects on the nutritional status of patients (114). Malnutrition 
commonly arises from inadequate protein or calorie intake, increased energy expenditure, 
dialytic nutrient loss, metabolic acidosis, dialysis induced catabolism, hormonal alterations and 
infection. Albumin may be a marker of nutritional status but is also reduced by acute illness. 
1.5.6.5. Bacterial infection 
Bacteraemia is a common problem in dialysis patients (115). Sepsis ranks second behind 
cardiovascular disease as cause of death in patients treated with long-term dialysis. Infections 
rates continue to be high despite application of infection- control programmes in many dialysis 
facilities. Many of these infections are dialysis access related but other infections are also 
frequent. They include respiratory tract infections, endocarditis, skin and soft tissue infections 
and urinary tract infections. Yascular access related infections are commonly caused by 
Staphylococcus aureus. Elderly and diabetic patients as well as those using catheters for 
vascular access are more vulnerable to infections. Uraemia causes reduced leukocyte 
chemotaxis and phagocytosis, increasing susceptibility to infection (116). The treatment of 
infections may be further complicated by increased antibiotic resistance in dialysis patients due 
to repeated exposure to antibiotics. 
1.5.6.6. Viral hepatitis 
Patients undergoing HD have excess risk for acquiring blood bourne virus infections. The 
prevalence of hepatitis B and hepatitis C virus (HBY and HCY) infections in dialysis- treated 
patients is commonly higher than the general population (117, 118). HBY and/or HCY 
infections in dialysis patients increase morbidity and mortality risks due to liver disease and 
reduced immunity. The prevalence and incidence of HBY and HCY infections among dialysis 
patients varies widely between countries and also within the same country and it correlates 
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with the prevalence in the general population. Global data indicate that the prevalence ofHBY 
and HCY infection is high in the populations of Africa and the Middle-East regions (l19-121). 
The overall prevalence of both infections in maintenance dialysis patients is decreasing in 
many countries. The prevalence of HBY infection in dialysis patients in Western Europe and 
the United States ranges between 0% and 7% (122) . Reports from Hong Kong and Brazil 
showed higher prevalence of approximately 10% (123, 124). Data from Saudi Arabia showed a 
prevalence rate of 4.6% (19) and from Jordan of 5.9% (125). A low rate of 1.6% was reported 
in Japan. The prevalence of HCY sero-positivity, on the other hand, is generally higher than 
HBY in dialysis populations though it differs widely between countries. Previous 
epidemiological studies have shown that the prevalence of HCY sero-positivity among patients 
receiving HD varies from as low as 6.1 % in Germany (l26) to as high as 76% in Casablanca 
(127). Reports showed that the prevalence of HCY sero-positivity in HD patients was 50% in 
Saudi Arabia (128), 42% in Tunisia (129),20.2% in Turkey (130) and 21 % in Jordan (20). 
Incidence of hepatitis B surface antigen (HBsAg) seroconversion is declining in many dialysis 
facilities due to adherence to strict isolation of seropositive patients and administration of HBY 
vaccine to seronegative patients. The incidence rate in majority offacilities (78.1%) in Western 
Europe and the United States included in the Dialysis Outcome and Practice Patterns Study 
(DOPPS) was 0 per 100 patient-years (122). Rates of annual HBY seroconversion are higher in 
developing countries. The incidence of HCY sero-conversion in Saudi HD patients was 
reported to be 7-9% per year (19) while in Jordan it was 2.6% (20). 
Multiple factors contribute to the increased risk of HBY and HCY infections among dialysis 
patients. Observational studies carried out in various centres worldwide have shown that the 
number of blood units transfused (126, 131), the duration of HD (131-134), a history of 
previous renal transplant (134-136), presence of HBY and/or HCY positive patients in the 
same facility and non-isolation of seropositive patients are associated with an increased risk of 
infection (137, 138). Historically, blood transfusion was the main factor implicated in 
transmission ofHCY infections in dialysis patients. Despite increased safety of blood products 
and reducing the need for blood transfusion by the use of recombinant erythropoietin hormone, 
transmission by this route seems to be still occurring in some countries, probably because of 
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delayed appearance of serological markers in some blood donors or poor quality of laboratory 
testing (139). 
Additionally, HD patients are predisposed to nosocomial transmission of HBV and HCV 
infections from seropositive patients because each treatment is associated with a small amount 
of blood loss from needling sites and discarded lines (140, 141). The most effective measure 
for preventing this is to isolate seropositive patients to dialysis stations in separate rooms but 
strict application of infection control procedures including safe disposal of contaminated 
medical waste are also important. Patient to patient transmission is confirmed by demonstrating 
similarity of subtypes and genotypes in patients receiving treatment in the same HD centre, 
sharing the same room or sharing the same HD machine (142). 
1.5.6.7. Vascular Access related complications 
Creating and maintaining a successful permanent vascular access is a major challenge for HD 
staff even in advanced and well organized health care systems because of a high incidence of 
dysfunction and failure. The need for secondary intervention to maintain vascular access is 
common. Furthermore, failure of new A VF to mature is observed in at least one third of cases 
(143). Data from DOPPS III (2005-2007) from II countries showed wide variation in vascular 
access patterns among countries with a highest rate of A VF use (91 %) in Japan and the lowest 
rate (47%) in the United States. Vascular access related complications account for 16-25% of 
hospital admissions in dialysis patients and depending on the type of vascular access in use, 
this correlated with overall and cause-specific mortality (84). Similarly, the USRDS (201 I) 
reported that HD access failure was the most frequent cause of hospitalisation. 
Late referral and lack of predialysis nephrology care are the main reasons for high rates of 
CVC use at dialysis initiation. DOPPS II reported that 23-73% of patients new to ESKD used a 
catheter for the initiation of HD (144). Barriers to A VF placement are patient preference, 
unfavourable anatomy, lack of surgical expertise and late referral of patients to nephrologists 
and vascular surgeons (145-147). Diabetes has also been identified as a risk factor for reduced 
utilisation of A VFs (91, 148, 149). 
Thrombosis is a leading cause of vascular access failure. Early thrombosis is associated with 
poor outcome as salvage is not usually attempted due to low success rates. Late thrombosis is 
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usually related to an underlying stenosis of the fistula and a variety of monitoring techniques 
have been developed to detect stenosis before thrombosis occurs. Vascular access related 
infection is a serious complication which often results in hospitalisation. Infections account for 
approximately 15% of all deaths in this patient population and for about one-fifth of 
admissions. Infections are usually associated with eves. Most studies showed that the risk of 
vascular access related bacteraemia is greatest with temporary eves and decreases 
progressively with tunnelled eves, AVGs and AVFs (150-153). Damage and weakening of 
the vessel wall following repeated cannulation can also lead to excessive dilatation and 
aneurysm formation. 
1.6. Survival of maintenance dialysis patients 
Despite optimal treatment, patients on maintenance dialysis have substantially reduced survival 
rates when compared to the general population. Patient survival is therefore the most 
fundamental outcome measure for patients receiving dialysis. Survival trends are best 
described by longitudinal observational studies such as those obtained from renal registry data. 
In the short term, annual mortality rate is recognised as a useful tool to assess and compare 
dialysis outcomes between different providers. A considerable body of research aimed at 
determining the factors associated with excess risk of death in dialysis patients has led to 
multiple reforms in the clinical practice guidelines. Mortality rates have declined modestly in 
the United States, Europe and Japan over the last two decades after modifiable risk factors for 
reduced survival were targeted (10, 154). 
1.6.1. Factors associated with increased mortality in dialysis 
patients 
Excess risk of death in patients receiving maintenance dialysis is related to multiple interacting 
factors that include; 
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• Factors related to characteristics of dialysis patients such as demographic and 
socio-economic status (155), timing and quality of predialysis nephrology 
care (156), pattern of initiation of dialysis and presence and type of 
comorbidity (157). Most accompanying diseases adversely affect survival. 
Patients with CKD have a higher prevalence and incidence of cardiovascular 
disease such as ischemic heart diseases and heart failure (158, 159). Other 
patient factors associated with elevated mortality rate includes; diabetes, 
hypertension, hypotension, smoking, dyslipidaemia, inactive life style, 
arteriosclerosis, malnutrition abnormal bone and mineral metabolism and 
male gender (160-164). 
• Factors related to the delivery of dialysis such as the mode of dialysis, 
location of dialysis facility, presence of trained staff, availability of 
resources, technical support, water quality and infection control polices (165-
168). In addition, quality of services in terms of number of sessions per 
week, delivered kt/v and monitoring of biochemical and nutritional indicators 
as well as social and psychological support (169-172). 
Mortality rates are high in patients receiving maintenance dialysis. The adjusted rates of all-
cause mortality are 6.5-7.4 times greater for dialysis patients than for individuals in the general 
population (10). USRDS (2011) data showed that only 50% of dialysis patients were alive 
three years after the start of ESKD therapy (10). At the time of initiation of dialysis, the 
expected life span ranged from approximately 8 years for patients aged 40-44 years to 
approximately 4.5 years for those 60-64 years of age (10). The risk of death increased with age 
and was higher in older men than women (10). The adjusted all- cause mortality among 
prevalent patients (2009) for the age group 45-64 years was 15.4% and for those who were 65 
years or more was 31.3% (10). In a recently published analysis of the ERA-EDTA Registry, 
the mortality rate in incident dialysis patients was 19.2 per 100 person-years, while it was only 
12.05 per 100 patient years in the general population (173). In Japan, the annual death rate has 
decreased over several years, recently to less than 10% (174). 
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1.6.2. Causes of death in dialysis patients 
Cardiovascular disease is the most common cause of death in dialysis patients and includes 
ischemic heart disease, arrhythmias, congestive heart failure and cardiomyopathy. The HEMO 
Study identified ischemic heart disease to be a major cause of cardiac deaths (61.5%) {I 75). 
Vascular diseases such as arteriosclerosis, arterial calcification and aortic aneurysm are also 
important factors associated with mortality. The aetiology of cardiovascular diseases in dialysis 
patient is not fully understood. In addition to a high prevalence of traditional cardiovascular 
risk factors a variety of dialysis related factors probably play a role including the state of 
uraemia, hypervolaemia, hypertension, metabolic acidosis, hyperparathyroidism, B-2-
microglobulinaemia and elevated endotoxins in patients. Stroke is common in dialysis patients 
and it is associated with poor outcome. Results of the HEMO Study showed that 
cerebrovascular death in maintenance HD patients was associated with diabetes, lower albumin 
level, greater heamatocrit and lower body mass index {I 76). 
The uraemic state also induces immunosuppression which may contribute to excess infection 
rates in these patients. Infection is the cause of death in approximately 15% to 30% of all 
dialysis patients (177). Septicaemia and pneumonia are the most common infections associated 
with death. The presence of a CVC is the most important cause for septicaemia leading to 
death in HD patients. Low physical activity levels, muscle wasting, weakness and frailty are 
also associated with an increased risk of death in dialysis patients (178). 
1.7. Renal Registries and research in dialysis 
1.7.1. Renal registries 
In many countries a renal registry has been established to collect and analyse data regarding 
mUltiple aspects of kidney disease and its treatment. Data from dialysis and transplantation 
programmes are collected at regular intervals and analysed to yield national data. The aim of a 
renal registry is to provide an ongoing audit of national data to inform efforts to improve 
treatment outcomes and to facilitate research. Registries are useful in characterising the ESKD 
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population, describing the incidence and prevalence of ESKD as well as trends in mortality and 
morbidity. They act as a good tool to investigate relationships between patient demographics, 
treatment modalities, clinical management and morbidity (179). Renal registries provide 
powerful epidemiology data because they have access to nationally comprehensive patient-
level data and track outcomes. Data provided by renal registries are used by health care 
authorities in planning the provision of dialysis services and to predict future expansion. 
Moreover, renal registry data should play an important role in the development of clinical 
practice guidelines as they represent an important source of evidence to inform best practice. 
Registry information also helps in auditing dialysis services by studying the variation in key 
indicators. A yearly report is usually published to help health care providers assess their 
performance and facilitate improvement programmes. Accuracy of information pooled from 
the peripheral centres as well as standardising the statistical methodology to allow international 
comparisons are important challenges for renal registries. Absence of a renal registry in some 
countries limits data to small observational series or reports, making it difficult to draw 
conclusions that could be applied nationally. 
1. 7.2. Dialysis related research 
As a relatively new form of therapy associated with multiple adverse effects, dialysis has 
attracted the attention of researchers seeking to evaluate outcomes and develop methods for 
improving them. Results from renal registry reports as well as other research have highlighted 
major differences in the quantity and quality of dialysis provision across the world. The 
variations are partially explained by disparity in demography of different regions, ethnicity, 
social disparity, economic status and prevalence of diabetes and hypertension in communities. 
The provision of dialysis is also strongly related to the wealth and overall development of a 
society. 
Over the past 10 years, monitoring and improvement of dialysis practice has led to the 
development of several sets of clinical practice guidelines, such as those of the NKF/KDOQI, 
to help practitioners provide the best possible care. 
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In addition to renal registries, a considerable body of research has evaluated clinical practice in 
dialysis provision and its relation to outcomes. Important projects in this regard include: 
1.7.2.1. Dialysis Outcome and Practice Patterns Study (DOPPS) 
(http://www.dopps.org/) 
DOPPS is a prospective cohort study of dialysis practice based on the collection of 
observational longitudinal data on patients from a representative and random sample of units in 
12 countries (Australia, Belgium, Canada, France, Germany, Japan, Italy, New Zealand, Spain, 
Sweden, the United Kingdom and the United States). Data collection for the study has been on-
going since 1996 and has yielded detailed data on more than 38,000 patients in over 900 
dialysis facilities. DOPPS investigations focus on determining which dialysis practices are 
associated with the best patient outcomes, with the primary goal of improving patient 
longevity, quality of life and other outcomes. 
1. 7.2.2. The International Study of Health Care Organisation and 
Financing (ISHCOF) 
ISHCOF examines how the treatment of renal failure is paid for around the world and how the 
services are organised and delivered to the patients (180-182). The ISHCOF is a sub-study of 
DOPPS. 
1.7.2.3. Dialysis practice research 
Researchers in different countries have also studied many aspects of ESKD and dialysis (102, 
105, 183-185). Major aspects of dialysis practice that have been addressed include: 
• General trends in dialysis-treated ESKD such as incidence and prevalence rates, 
geographical, ethnic, gender and age variations as well as causes of ESKD and 
dialysis outcomes. 
• Indicators of provision of services, in terms of number and distribution of dialysis 
facilities, bed capacity, number of working days/week and working shifts/ day. 
29 
• 
• 
• 
• 
• 
A vailability of a qualified multidisciplinary team measured by the proportion of staff 
from each specialty to the number of patients treated. 
The complex effect of ESKD and dialysis on patient's health and the effect of 
coexisting comorbidity. 
Clinical and biochemical monitoring of dialysis patients in terms of adequacy of 
dialysis dose, control of anaemia, normalisation of bone mineral metabolism and 
sufficient nutrition. 
Nosocomial transmission of infections in dialysis units and methods to prevent them . 
Technical issues like biological and chemical quality of dialysis water and type of 
dialysis membrane used. 
• Measures to protect the environment through sanitary disposal of the dialysis 
consumables. 
1.8. Libya: Current social, demographic, economic and 
political factors impacting on health care 
The overall pattern of ESKD varies considerably according to the social, cultural and economic 
context of a country. Some important aspects about Libya will be briefly discussed. These 
aspects mostly apply to the time the study was undertaken, as major changes have occurred due 
to the internal conflict that began in February 2011. 
1.8.1. General features 
Libya is a vast country (4th largest country in Africa) with an area of 1,665,000 square 
kilometres. Its total population reached 5,673,031 persons in the 2006 census (186). Amongst 
these, 6% were non- Libyan residents. In spite of a low overall popUlation density of three 
persons per square kilometre, the majority (85%) of the country's popUlation are urban and live 
in the coastal regions. A map of Libya is shown in figure 1. 6. 
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Figure 1. 7: Map of Libya showing that most of the cities are in the coastal 
region. (http://www.who.int/countryfocusl) 
Geographically, it can be divided into a green coast and a wide desert. Approximately 88 % of 
the population lives in the north, near the Mediterranean coast and in the region of the North 
West and East Mountains chains. The other 12% live in small towns scattered in the Libyan 
Sahara around valleys and oases. Perpetual drought means that Libya faces strong constraints 
in terms of availability of water resources and offood self-sufficiency (187). 
Administratively, the country is divided into 22 municipalities. Each municipality is divided 
into communes, which is the basic people's congress. The total number of Libyan communes is 
468. The members of each commune meet periodically to discuss political, economic and 
social issues. 
Libya has massively developed its infrastructure and human resources over the past 50 years. 
The economy depends primarily upon revenues from the oil sector, which contribute about 
95% of export earnings, about one quarter of Gross Domestic Product and 60% of public sector 
wages. Libya is considered to have one of the highest per capita Gross Domestic Products in 
Africa. Overall, it is classified as a medium- developed country in the United Nations 
Development Programme 's Human Development Index, where it is ranked 58 th out of 178 
countries (www.nationmaster.com). Generally, most development indicators are among the 
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best in the African continent and above the mean for the Arab world. For example, life 
expectancy at birth as reported in 2007 was 77 years (www.cia.gov/libral)'/publications/the-
world-factbookl). 
1.8.2. Social constitution 
Libya's social and cultural characteristics are similar in many aspects to other Arab countries. 
Libyans tend to live in either nuclear or extended families where they maintain strong social 
relationships. Most communities are stable with minimal migration rates. As a conservative 
tradition, most boys and girls live in the family's house until their marriage. Chronically ill and 
disabled persons are looked after by family members. Almost no nursing homes are available 
in the country and just a few rehabilitation institutions in the main cities. 
Several cultural features of the Libyan society probably adversely affect people's health and 
increase the risk for CKD either directly or indirectly. First, people in this country tend to 
adopt a sedental)' life style (188). Physical activity is vel)' limited especially among women. A 
population based study was undertaken in the town of Tajoura, in the west of Libya which 
included 2996 adults showed that only 18% of surveyed people were practicing any form of 
physical exercise and more than 69% had a body mass index of more than 25 kg/m2 (\88). 
Physical work including construction, agriculture and industry is carried out mostly by 
expatriate labour. Private transport (mainly cars and minibuses) is considered socially superior 
to walking as it expresses wealth. Additional factors that contribute to Libyans' inactive way of 
life include; the habit of socialization by visiting each other indoors, the hot sunny weather 
which inhibits walking during day time, the poorly developed pedestrian and cycling 
infrastructure, the shortage of public green areas in most cities and the lack of well-structured 
health education programs. 
Libya has an average of six deaths per day due to road traffic accidents and according to the 
figures for 2009 alone, over 14,000 injuries from road traffic accidents, almost half of which 
were severe. Road fatalities are 31.5 per 100,000 population in comparison with 6.1 in the UK 
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(http://www.emro.who.intl). According to World Health Organisation reports, Libya has one of 
the highest death rates from road traffic accidents in the region. 
The second cultural aspect which negatively affects people's health is the Libyan diet (189). It 
is rich in carbohydrates and fats but poor in fresh vegetables. Meat and poultry are principle 
ingredients in many local daily dishes (190). This diet is dense in energy and poor in 
micronutrients (189). Consequently adults especially women are affected by a high prevalence 
of overweight and obesity. A recent survey showed that 15.5% of 13-15 year-old school 
children assessed were overweight and 6.1 % were obese (186). Deficiency in micronutrients 
like iron is highly prevalent (191). Reports also showed that about 30% of the adult male 
Libyan population are regular smokers (186). 
Currently, awareness among the public of the risks of this negative life style has substantially 
increased due to media coverage, but only a minority have actually changed their lifestyles. 
1.8.3. Social security system 
Libyans benefit from a social security program, which promotes welfare of people in the event 
of old age, disability, sickness, accidents, occupational diseases, childbirth and unemployment 
(192). A basic pension is payable to all disabled persons, including all ESKD patients receiving 
any mode ofRRT. The amount depends on the type of previous work, years of experience and 
the extent of the disability. 
1.8.4. Health care system 
Since the early 1970's, Libya has attained marked improvements in the health care sector. 
Expansion was made possible by building hospitals, polyclinics, laboratories, medical schools 
and other health care infrastructure (186). Training the necessary work force to deliver health 
care services for the expanding sector was undertaken in parallel with building of facilities 
(186). Some recent indicators of the health care sector reported in 2007 are shown in Table I. 
2. 
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Table 1. 2: Indicators of health care sector in Libya (WHO Statistical 
Information System. (http://www.emro.who.intlemrinfo/index) 
Primary health care centres 1424 
General Hospitals 21 
Central Hospitals 18 
Provincial Hospitals 32 
Specialized Hospitals 25 
Number of doctors/I 0.000 17 
Number ofnurses/IO.000 50 
Number of Hospital beds/I 0.000 37 
Although health care services are available and free for all citizens and residents in Libya, their 
quality is SUboptimal. A state budget is allocated each year to cover the cost of health care 
delivery. A recent estimation of the total expenditure on health per capita is $298 per year, 
which is considered medium for countries in the region but low for the developed nations 
(http://www.emro.who.intiemrinfo/index). The main causes of death reported by national 
authorities in 20 I 0 were cardiovascular diseases (37%), cancer (13%) and diabetes (5%). Road 
traffic injuries accounted for II % of all deaths. 
However, Libya's health care system suffered greatly in the 1980's and 1990's because of the 
United Nation's sanctions and Libya's isolation from other countries (186). Sanctions included 
medical equipment and technology as well as technical support. Education, training abroad and 
representation of Libya in scientific organisations was suspended. Many qualified doctors 
moved outside the country, which resulted in a 'brain drain' and loss of expertise (193). 
Sanctions markedly affected the young and fragile health care system. After the lifting of 
sanctions, enormous deficiencies in the health care services were obvious. Health care policy 
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makers planned for rapid growth to meet the consumer's expectations and to catch up with 
ever-increasing demand. Lately arguments between the users and staff about the overt 
deficiency of the Libyan's health care system and its inefficiency had have arisen (194). A 
decision to reform the health care sector with the explicit aim of improving performance was 
recently undertaken. It included introducing many organisational changes. An important 
example is recruiting hundreds of young medical practitioners from different specialties to 
enrol in a specially tailored family physicians graduate program in order to form the nucleus of 
family practice in the country. Generally, the rehabilitation of the health care system in Libya 
was ineffective due to lack of proper organisation, mismanagement, negligence and corruption. 
In practice, the Libyan health care system has always been dominated by the idea of treating 
patients rather than promoting the health of people and preventing them from becoming ill. A 
large amount of the health care budget is spent in purchasing modem sophisticated technology 
and expensive medication, which are used mainly at secondary and tertiary care level while 
most primary health care (PHC) facilities experience shortage of basic equipment and medicine 
(194). Furthermore, despite the expansion of PHC facilities throughout the country, there is no 
system to sustain a link between local people and their PHC facilities. People are not directed 
to register with a PHC facility. Instead, they just walk in to any PHC centre whenever they fall 
sick and/or are exposed to injury. Staff in the PHC focus primarily on treating urgent problems 
or referring patients to the secondary care level. Clinics in PHC are staffed principally with 
inexperienced medical graduates. Many of them lack job satisfaction because of a deprived 
work environment, lack of education and training programs and low income as compared to 
their counterparts working in hospitals. Nursing and medical technology staff are local 
graduates who are inadequately trained resulting in a poor quality of practice. 
Collectively, several factors worsen the state of mistrust between people and the health care 
system. Even in the secondary and tertiary health care levels, Libya still finds itself facing a 
shortage of specialists in a number of key areas such as family medicine, anaesthesia, 
nephrology, cardiology and radiology. Despite large numbers of medical students and large 
amounts of funding for scholarships for doctors to specialize abroad, many choose to make 
their careers abroad (http://www.who.intlcountries/lby/en/). Recently, the General Medical 
Council confirmed that there are 707 doctors registered in the UK who obtained their primary 
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medical qualifications in Libya (195). Another negative contributory factor is an inadequate 
standard of nursing care due to poor quality nursing education and training. 
1.8.5. Health records 
Medical records are necessary to retain all relevant data about a patient that clinicians need to 
support clinical decision making at the point of care. Unfortunately, almost no medical records 
are kept in the PHC facilities. At secondary and tertiary care levels, a traditional paper record is 
maintained for each patient for saving all clinical and administrative patient information, 
including laboratory results, pharmacy orders, radiology reports, medical graphs, 
electrocardiograms and nursing as well as physician notes (196). Records are sent to the 
medical information department to be kept in the archives shortly after a patient's discharge or 
death. In many hospitals, however, medical archives are poorly organised and difficult to 
access. Consequently, capturing longitudinal data is difficult. Recently, a trial of electronic 
medical records was initiated in a small number of hospitals. Economic constraints on the 
health care sector make expansion of these trials slow. 
ESKD patients are among the patients adversely affected by the medical record system because 
their significant past medical history and other medical data generated at the time of diagnosis 
in hospitals are kept locked in hospital archives. Patients are sent to dialysis units with a brief 
referral report only. In dialysis facilities, a new medical record is provided for each patient. It is 
mainly concerned with reporting dialysis-related information. 
1.8.6. Medical research 
Medical publications are indicators of the quality of health care services and medical education 
in countries (197, 198). Medical education in Libya does not emphasize medical research in 
undergraduate or postgraduate studies. Moreover, the underdeveloped research environment in 
many Libyan health care and academic facilities exacerbated by the absence of research funds 
and incentives hinders health related research and makes it a low priority for medical staff 
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(199, 200). The annual publication rate for academic staff in peer-reviewed journals is 
estimated to be around 0.7 publications/JOO staff, which is considered among the lowest rates 
in the middle east region (201). 
1.8.7. Diagnosis of ESKD cases and referral for RRT in Libya 
The typical mode of presentation with ESKD is for a young or middle-aged person with 
insignificant past medical history to be rushed to a clinic after the development of uraemic 
symptoms. Such patients usually present themselves to PHC, general hospitals or private 
clinics. Once the diagnosis of ESKD had been confirmed by laboratory tests, patients are 
usually referred urgently to medical/nephrology departments to receive HD through a CVC. 
Patients and their families experience sudden emotional shock, especially if the case is 
unprecedented within the family. In many instances, people do not believe the doctor's 
unexpected diagnosis because they lack trust in the local health care system and seek another 
opinion either within or outside the country. Several patients travel abroad for consultation and 
treatment in Tunisia, Egypt, Jordan and further (202). Finally, most patients who survive the 
initial critical period of illness are established on chronic HD in the nearest dialysis centre. 
Discussion about other options for RRT and/or vascular access usually starts later on. 
The second less dramatic and less common scenario is of a middle aged or old person who has 
an established renal, urologic or chronic systemic illness that are known to affect kidney 
function. These patients are usually offered nephrology consultation, follow up and treatment 
when they were diagnosed as having CKD. They usually take part in decisions about the type 
and the timing ofRRT. 
1.8.8. Renal replacement therapy in Libya 
All types of RRT are funded by the state. All available services are delivered to citizens and 
residents free of charge. However, because of their enormoUS cost, these services are provided 
exclusively by the public sector. 
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The first HD service in the country was started in Aljemhoria Hospital in Benghazi city in 
1973. This service gradually expanded in numbers of both patients and centres. PD was 
introduced as a trial in the 1990's but has remained at very low level. Kidney transplantation 
was introduced into the country as a collaborative project between Poland and Libya in 1988. 
A renal transplant unit was founded in Alzahra Kidney Centre near Tripoli city. Polish 
surgeons transplanted 63 kidneys from live related donors during 8 years. Eventually, 
transplantation activities collapsed, largely due to United Nation's sanctions against Libya and 
subsequent shortage of the immunosuppressive therapy as well as medical equipment. 
In 2004 after sanctions were removed, a new transplantation program was initiated in Tripoli 
Central Hospital (203). Reports show approximately 45 renal transplants per year (204). 
However, organ transplantation in Libya depends exclusively on the availability of a suitable 
living related donor (205). Living donors are not available for many ESKD patients as many 
possible donors are ineligible due to familial renal disease, diabetes or hypertension. 
Consequently the gap between patients' needs and the transplantation rate continues to widen. 
Social pressures prompt many medium and wealthy families to seek kidneys from the poor in 
other countries. A recent survey showed that about 19% of renal transplants among Libyans 
were carried out in Libya whereas the majority were transplanted abroad, mostly from living 
non-related donors (206), a practice which encourages organ trafficking and exploitation. After 
being transplanted abroad, patients often return to the country with minimal and indistinct 
medical information leaving the Libyan health care system to stabilize them and provide long 
term care. 
A deceased organ donation program was initiated in the country by launching educational 
campaigns through the media to familiarize people with the concept and motivate them to sign 
a donor card. However, cadaveric donation in Libya is still hampered by lack of proper 
knowledge, religious misconception and other psychological factors (207). All renal transplant 
activities were suspended at the start of the revolution in February 2011 and remain suspended 
to date. 
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1.8.9. Recent conflict in Libya 
A political clash started in Libya during February 20 II when protestors took to the streets 
throughout the nation demanding their human rights from a dictator who had dominated the 
country for 42 years (208). The regime responded with violent offences against the people and 
this provoked a war which took 8 months to resolve (209). The impact of the conflict is obvious 
in all life aspects. The health care sector has been massively affected, with many PHC facilities 
closed because of damage sustained during the fighting, acute shortage of medicines and 
supplies and departure of many of the expatriate medical staff (210, 211). During the crises, 
most local staff, volunteers and many international humanitarian organisations collaborated to 
manage trauma and war injuries but shortage of services and medications affected chronically 
ill people and added to the overall mortality (212, 213). However, reports about fatalities due to 
lack of health services during the fighting are not available. Thus, a detailed post conflict 
assessment of the health care system is required. 
1.8.10. The need for studying the epidemiology of end-stage 
kidney disease in Libya 
With the absence of a renal registry and population based epidemiological surveys in Libya, 
little information is available regarding the extent of renal failure in this community or the 
patterns of dialysis practice in different health care facilities. Furthermore, the quality and the 
outcome of medical care provided for dialysis patients have not been described. This 
knowledge gap necessitates scientific work to generate local data to inform the planning of 
future development and help in improving the quality of dialysis delivery as well as its 
outcomes. 
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2. Aim and objectives 
2. 1. Aim 
The aim of this thesis is to assess the epidemiological patterns of ESKD in adult patients and 
dialysis- treatment quality as well as outcomes. 
To achieve this, the following objectives were framed: 
2. 2. Objectives 
• 
• 
To assess the provision and quality of maintenance dialysis services in Libya . 
To determine the annual incidence, prevalence and causes of ESKD treated with 
dialysis in the adult population. 
• To investigate the incidence and prevalence of HBV and HeV infection in the HD 
population of Libya as well as risk factors for infection. 
• To determine the patterns of vascular access utilisation in Libya and risk factors 
associated with failure of permanent vascular access. 
• To investigate survival rates, determinants of survival and causes of death in the 
dialysis population. 
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3. Methods 
This chapter describes all methods applied in this thesis. The methods comprise those common 
to all aspects of the research and others relevant only to specific analyses. The latter will be 
described in more detail in the relevant results chapters. 
3. 1. Study location 
The study was performed by a Libyan researcher with support and guidance provided by a 
supervisors based in a Nephrology Department in the United Kingdom. The study plan and 
design was developed in the United Kingdom. All data were collected in Libya. Finally, data 
analysis and writing up were performed in the United Kingdom. 
3. 2. Ethical approval 
Permission to conduct the study was granted by the Ministry of Health in Libya. Ethical 
approval for the research was obtained from the Libyan National Committee for Bioethics and 
Bio-safety. Patients were requested to participate in the study and each gave written informed 
consent before conducting the interview. 
3. 3. Pilot study 
A pilot study was undertaken in 5 dialysis units. The dialysis facility questionnaire was tested 
in four dialysis centres and validated through discussion with the clinical directors of surveyed 
centres. The dialysis patient questionnaire was tested in a sample of 100 patients (20 from each 
dialysis facility). Difficulties including poor quality of medical records, variation in patient 
management systems and the need to recruit a local research team were explored and solutions 
developed. 
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3. 4. Study plan 
• 
• 
• 
• 
• 
Collection of contact information for all maintenance dialysis facilities in Libya . 
Face to face interview with the supervisors of 28 of 40 maintenance dialysis facilities 
in Libya, including one paediatric unit. 
Telephonic interview with the supervisors of the remaining 12 maintenance dialysis 
facilities. 
Clinical supervisors of the 12 dialysis centres not visited were requested to complete a 
data collection form about each adult patient receiving maintenance dialysis in the 
facility including CAPD cases ifpresent. Forms sent by special delivery and collected 
back after 30 days. 
28 maintenance dialysis facilities were visited by research team (The paediatric unit 
was not visited for patient interviews). All available dialysis patients were approached 
and interview requested to obtain detailed medical and social information. 
• Frequent contacts to all maintenance dialysis facilities during I-year follow-up and 
repeated visits or phone calls to obtain information about patient's outcome and 
enrolment of new cases. 
• Follow-up study of all patients recruited to initial cross-sectional study after I year. 
3. 5. Research team 
Apart from the principal researcher (the author) and two consultant Nephrologists based in 
Renal Unit in The United Kingdom (the supervisors), the research team included; 
Ten medical graduates from different cities in Libya who chose to make joining this study part 
of their internship training. They participated in data collection at their local maintenance 
dialysis facilities. 
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Three medical researchers were appointed by the Libyan National Authority for Scientific 
Research. They provided assistance in gathering data from some maintenance dialysis 
facilities. 
3. 6. Study design 
• 
• 
• 
• 
Cross-sectional study of dialysis centres was performed from May to August 2009. 
Cross-sectional study of maintenance dialysis patients was performed from May to 
August 2009. 
Longitudinal study of maintenance dialysis patients was performed from September 
2009 to August 2010. 
Follow-up study of all patients recruited to initial cross-sectional study from August to 
December 2010 
3. 7. Study duration 
36 months of which data collection took 20 months. 
3. 8. Study data 
3. 8. 1. Dialysis facility data 
Medical directors of dialysis facilities in Libya were contacted initially by phone, informed 
about the study and asked to participate by answering the questions either by phone or by face 
to face interview. The principal researcher (the author) visited 28 dialysis facilities (one of 
them was serving children only) and interviewed the clinical directors of the remaining 12 
facilities by telephone. A structured questionnaire was designed to lead the interview. It 
included four main groups of questions: dialysis capacity, staffing, methods of assessment of 
dialysis patients and infection control measures. Each personal interview took around 30 
45 
minutes while telephone interviews were generally shorter. Each principal contact was 
interviewed once. Further telephone calls were made to almost all centres to collect missing 
data, mostly recent statistics regarding patients and staff. In all dialysis centres visited, the head 
of the facility invited researchers to view the facility. 
3. 8. 2. Dialysis patient data 
Brief demographic and clinical information were collected for all dialysis patients in Libya 
included date of birth, gender, ethnicity, nationality, height, weight, type of dialysis, date of 
dialysis initiation, primary kidney disease, previous renal transplantation, haemoglobin value 
and sero-positivity for hepatitis Band/or C virus. Date of birth was recorded if known. 
Otherwise, the year of birth was used. The same applied for the date of first dialysis. Primary 
kidney disease was recorded according to the opinion of the treating physician or medical 
reports when available. For the 28 facilities visited (paediatric only facility was excluded from 
dialysis patient-related study) data was collected by the research team. For the remaining 12 
remote dialysis facilities data collection sheets were distributed to the clinical supervisor for 
completion. Frequent phone calls were used to answer queries and ensure that data were 
correctly documented. 
The dialysis patient questionnaire included social history, history of smoking, physical 
independency, detailed clinical history, presentation of ESKD and any history of 
hospitalisation at the time of initiation of dialysis, family history of CKD, history of previous 
blood transfusion (if yes, patients were asked about the frequency of transfusions). For patients 
treated with HD, other questions included: HD hours per week, history of receiving HD in 
another centre inside Libya or abroad, type and site of vascular access used for HD, history of 
previous vascular access-related complications and hospitalisations, mean pre-dialysis blood 
pressure over one week before the interview and erythropoietin treatment. Available recent 
investigation results were collected and recorded for all dialysis patients including: 
haematocrit, alanine aminotransferase and aspartate aminotransferase concentration, serum 
albumin and predialysis serum urea and creatinine concentrations. 
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The principal researcher was responsible for obtaining consent and undertaking interviews 
while the research team collected information by inspecting medical records as well as asking 
the treating staff about missing information. 
3. 9. Follow up data 
Follow-up included two types of data. First, follow-up and outcome data were collected for 
every patient included in from May to August 2009 study. Data was collected from August to 
December 2010. Variables were similar to those used during the cross-sectional study and 
similar data collection forms were used. Questions added included admission to hospital during 
the follow up year (and the reason for admission) and sero-conversion to HBV or HCV in 
previously sero-negative HD patients. The second set of data was brief demographic and 
clinical information of all new ESKD patients who joined dialysis facilities during the follow-
up time (August to December 20 I 0). The research team conducted data collection frequently 
during the year to ensure the inclusion of every new patient in the country. Subsequently, 
researchers conducted field visits to dialysis facilities from August to December 2010 to 
validate the information. 
3. 10. Frequency of assessments and timing 
Clinical supervisors of the maintenance dialysis facilities were interviewed once. Each personal 
interview took around 30 minutes while telephone interviews were generally shorter. Each 
patient receiving maintenance dialysis was interviewed twice while they were in the dialysis 
facility, first at recruitment and then again after I year. The first interview took approximately 
30 minutes while the second was relatively shorter. 
3. 11. SUbjects and centre selection (inclusion criteria) 
• All Libyan maintenance dialysis facilities (n=40) providing services during May to 
August 2009 were included in the initial study of dialysis provision. 
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• Regarding individuals, this study included all adult (16 years or older) patients 
receiving dialysis in Libya between May 2009 and December 20 I O. 
3. 12. Statistical analysis 
Information about the maintenance dialysis facilities on the questionnaire sheet was coded and 
entered into a spreadsheet for analysis using SPSS 16.0. (SPSS, Inc., Chicago, IL, USA). 
Descriptive analyses were employed as appropriate. 
Information collected about maintenance dialysis- treated patients was revised and cross 
checked for patients who were known to receiving dialysis in another centre within the 
country. Data coded and entered into a spreadsheet for analysis using SSPS 16.0. (SPSS, Inc., 
Chicago, IL, USA). Data presented as mean, standard deviation if normally distributed or 
median (interquartile range) if not. A Chi-squared test was used to evaluate the significance of 
relations between categorical variables. Correlations were tested with a Pearson's test. A I-test 
was used to compare means between groups for data with normal distribution or Mann-
Whitney test for non-parametric data. Multivariable binary logistic regression was used in 
certain analyses to identifY independent determinants of dependent variables. A P-value of 
<0.05 was considered statistically significant. 
3. 13. Data handling and record keeping 
Information regarding study subjects is kept safe and confidential. Data were anonymised 
before entry into a computer database. Study subjects or individual dialysis facilities are not 
identifiable in any publications. The researcher maintains a study master file that contains all 
the essential documents relating to the study. 
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4. Provision and quality of dialysis services in Libya 
4.1. Introduction 
The prevalence of ESKD is increasing worldwide. It is a chronic and irreversible condition 
associated with substantial morbidity, high mortality rates and large financial burden on health 
care systems (214-216). Dialysis remains the main technique for RR T due to a shortage of 
donated organs. Improving the quality of care for d i a l y s i ~ ~ patients through standardisation is 
associated with favourable outcomes (217-219) and several professional organizations have 
developed evidence-based guidelines to optimize the quality of care (220). 
Libya is a vast country with an area of 1,665,000 square kilometres (221). Its estimated total 
population was slightly over five and half million in 2009 (221). In spite of a low population 
density of three persons per square kilometre, the majority (85%) of the country's population 
are urban (222). Overall, it is classified as a medium- developed country in the United Nations 
Human Development Index (http://hdr.undp.orglenlstatistics). Per capita purchasing power 
parity was estimated as $14,000 in 20 I 0 which ranked the country as 83th compared to the 
world (https://www.cia.gov). However, about one-third of Libyans live at or below the national 
poverty line. Generally, development indicators are among the best in the African continent 
and above the mean for the Arab world (222). Dialysis services are offered free of charge to all 
referred patients regardless of their age. All dialysis facilities belong to the public sector and 
are funded by the Secretariat for Health and the Environment. Although dialysis has been 
provided in Libya for around 4 decades, no national dialysis practice guidelines are available to 
promote best practice. In fact, the provision of RRT in Libya has not been previously 
evaluated. Generally, there is lack of information about dialysis infrastructure and there is no 
renal registry to gather national data. This study was therefore undertaken to assess the 
provision and quality of current dialysis services in Libya to inform policy decision makers as 
well as caregivers and facilitate health care development in addition to the establishment of a 
Libyan renal registry. 
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4.2. Methods 
A cross-sectional study of all active Libyan dialysis centres was undertaken from May to 
August 2009. As there was no accurate list of names and contact information for dialysis 
centres in Libya, researchers contacted the national drug and medical supplies company to 
obtain a contact list. Disappointingly, even this list was deficient. Researchers subsequently 
contacted each general and specialized hospital in the country by phone and enquired about 
dialysis services within the hospital or in the region to complete the first comprehensive list of 
chronic dialysis units and contact details. Centres providing only acute dialysis were not 
included. 
A structured questionnaire was designed to lead the interview. It included four main groups of 
questions: dialysis capacity, staffing, methods of assessment of dialysis patients and infection 
control measures. The questionnaire was tested in four dialysis centres and validated through 
discussion with the clinical directors of surveyed centres. Ethical approval for the study was 
obtained from the Libyan National Committee for Bioethics and Bio-safety. 
Medical directors of dialysis units were contacted initially by phone, informed about the study 
and asked to participate by answering the questions either by phone or by face to face 
interview. All directors (n=40) agreed to participate in the study and 28 agreed to a face to face 
interview. Each personal interview took around 30 minutes while phone interview was 
generally shorter. Each principal contact was interviewed once. Further telephone calls were 
made to almost all centres to collect missing data, mostly recent statistics regarding patients 
and staff. In all dialysis centres visited, the head of the facility invited researchers to view the 
facility. 
Information on the questionnaire sheet was coded and entered into a spreadsheet for analysis 
using SPSS 16.0. Descriptive analyses were employed as appropriate. 
51 
4. 3. Results 
4. 3. 1. Dialysis capacity 
The first HD service in Libya was opened in Aljemhoria Hospital in Benghazi city in 1973. 
The number of patients and centres has increased over time (figure 4. I). PD was introduced to 
Libya as a trial in the late 1990's but utilisation has remained minimal. 
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Figure 4. 1: Increase in dialysis centres over time in Libya. 
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Table 4. I describes dialysis service capacity. A total of 2417 adult patients (approximately 60 
patients/ centre) were receiving maintenance dialysis therapy in 40 centres. The estimated 
population of Libya during 2009 was 5,488,444 (of which 29.4% were <15 years) giving an 
estimated adult population of 3,874,841. The prevalence of ESKD treated with dialysis in 
adult population of Libya was therefore approximately 624 pmp in the year 2009. 
Most dialysis patients (98%) were Libyans and the majority were over 15 years of age (98.8%). 
Median age of prevalent patients was 49 years (inter-quartile range 36-61 years). Median 
dialysis vintage was 3 years (inter-quartile range 1-6 years). Thirty-two (80%) dialysis units 
were located in the northern part of the country (mainly the coast, western and eastern 
mountainous regions) where 88.5% of inhabitants live. Thirty-five dialysis units (88%) were 
placed within a local hospital campus whereas 13% were free standing centres. Most centres 
(83%) accepted a mix of paediatric and adult patients (age range 8-90 years). However, 15% of 
dialysis centres treated only adult patients and one facility treated children only (age range 3-17 
years). Amongst dialysis centres, just three offered PD in the form of continuous ambulatory 
PD (CAPD) and all were located in the north. No automated PD and no home HD are currently 
offered. 
Dialysis shifts were 4 per day in one centre only, 3 per day in 7 {I 7%), 2 per day in 21 (52%) 
and one per day in 11 (27%). HD shifts generally started at around 7:00 am. Facilities that run 
evening shifts usually end by 10:00 pm. One centre scheduled treatments at night from 10:00 
pm to 2:00 am to accommodate a rise in number of patients requiring dialysis. Most large 
centres accepted new patients immediately and scheduled or referred them to another centre 
after stabilizing their condition. Dialysis facilities had different designs and room sizes. Table 
4. 1 shows that the total number of HD rooms was 192 (range 1-21 rooms per facility). They 
hosted 713 functioning HD stations (range 1-90 per facility), with a ratio of one machine to 2.8 
patients. The total number of non-utilised HD machines was 130. Of these 109 needed repairs 
whereas the remainder were kept as a reserve. The majority of patients were offered HD 3 
times a week. However, 6 facilities could not provide regular slots for new patients and they 
were therefore initially dialysed infrequently when slots were available. Most centres modify 
the frequency of treatment according to patients' medical condition and attendance. 
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All centres provided free supplies of adjunctive treatments for dialysis patients including those 
administered at the dialysis centres like erythropoietin and those which are administered at 
home such as iron, folic acid, vitamin D and calcium. However, all units experienced 
intermittent shortages of most types of medications. A service for creation of permanent 
vascular access was available locally in just 6 centres (15%). In the majority of centres patients 
were referred to vascular surgeons elsewhere. 
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Table 4. 1: Description of dialysis services in different regions of Libya. 
Total number of adult patients 
Prevalence 2009 (adults pmp) 
Dialysis centres located in hospital campus 
Dialysis provided for both adults and 
children 
Centres provide both haemodialysis and 
peritoneal dialysis 
Median number of working days/week 
[Range] 
One 
Two 
Working shifts/ day 
Three 
Four 
Regions 
North West 
N=21 (%) 
1558 
628 
18 (86) 
17(81) 
2 (10) 
6 
[3-7] 
3 
II 
6 
Number of dialysis rooms 106 
Number of all haemodialysis stations 490 
Number of working haemodialysis stations 429 
Median number of working haemodialysis 20 
station/centre 
[Range] 
[I -90] 
Haemodialysis stations to patients 1:3.2 
Local vascular access surgery 3 (14) 
Availability of educational materials 6 (29) 
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North 
East 
N=tI (%) 
653 
623 
10 (91) 
9 (82) 
I (9) 
6 
[5-6] 
5 
5 
o 
60 
253 
212 
16 
[4-61] 
I: 3.1 
3 (27) 
3 (27) 
South 
N=8(%) 
206 
597 
7 (88) 
8 (100) 
0(0) 
6 
(3-6] 
3 
5 
o 
o 
26 
100 
72 
7 
[4-23] 
1:2.9 
0(0) 
0(0) 
Total 
N=40(%) 
2417 
624 
35 (88) 
34(85) 
3 (8) 
6 
[3-7] 
I I (27) 
21 (52) 
7 (17) 
I (2) 
192 
843 
713 
15 
[1-90] 
1:3.4 
6 (15) 
9 (23) 
4. 3. 2. Staffing of dialysis facilities 
Table 4. 2 shows that a nephrologist or a physician was available on call for all dialysis 
sessions in 95% of centres. Approximately half of dialysis centres offered scheduled specialist 
consultations in outpatient clinics. Two remote centres in the South were delivering services 
without any doctors due to lack of staff. The total number of national and non-national doctors 
was 114 (doctor to patient ratio I :22). Among these, there were 53 junior physicians and 61 
qualified nephrologists/intemists (nephrologist/internist to patient ratio I :40). The overall 
number of trained dialysis nurses was 639 with a ratio of one nurse to 3.7 patients. Social 
workers and dieticians were available in 15 and 20% of dialysis facilities, respectively. 
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Table 4. 2: Staffing of dialysis centres in different regions of Libya 
Regions 
North West North East South Total 
N=21 (%) N=ll (%) N=8 (%) N=40(%) 
Centres with physician available on call at 21 (100) 11(100) 6 (75) 38 (95) 
all dialysis sessions 
Outpatient nephrology consultation 10 (48) 8 (73) 3 (38) 21 (53) 
Total number of junior doctors in region 39 9 5 53 
Median 0 0.5 
[Range] [0-10] [0-3] [0-2] [0-10] 
Total number ofnephrologists/ internists in 32 
region 
25 4 61 
Median 2 
0 
[Range] [0-4] [0-6] [0-2] [0-6] 
NephrologistslInternists to patient ratio 1: 49 1: 26 1: 52 1: 40 
Total number of trained dialysis nurses 379 169 93 641 
Median 15 11 11 11.5 
[Range] [2-90] [4-72] [6-26] [2-90] 
Nurse to patient ratio 1:4 1:4 1:2 1: 3.7 
Presence of social workers 5 (24) 1 (9) 0(0) 6 (15) 
Presence of dieticians 4 (19) 3 (27) I (13) 8 (20) 
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4. 3. 3. Assessment of maintenance dialysis patients 
Findings related to methods employed to monitor patients are described in table 4. 3. KDOQI 
guidelines were applied in only 4 dialysis centres. Pre, intra and post dialysis blood pressure 
were recorded routinely in all dialysis facilities as well as pre and post dialysis weight 
measurement. HD adequacy was monitored by Ktlv measurement in some patients in 10% of 
centres, whereas urea reduction ratio was used in 25% of centres. The remaining 28 centres 
including all centres in the south used a single monthly pre-dialysis urea measurement to 
monitor adequacy. Haemoglobin and haematocrit were monitored monthly in all centres. Only 
40% of centres had an established policy for anaemia monitoring by measuring serum ferritin 
and total iron binding capacity (T1BC). Another 15% assessed anaemia by measuring serum 
iron and TIBC. Mineral metabolism was evaluated by measurement of serum calcium and 
phosphorus in 85% of centres and by serum calcium only in 5%. No assessment of blood 
minerals was performed in 10%. Monitoring serum albumin as an indicator of nutritional status 
was done monthly in 58% of centres. Finally, parathyroid hormone levels were assessed in 
13% of centres. However, all centres experienced intermittent deficiency in laboratory supplies 
resulting in failure to perform required blood tests. 
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Table 4. 3: Monitoring of dialysis patients in different regions of Libya. 
Application of dialysis practice guidelines 
Pre, intra& post dialysis measurement of 
blood pressure 
Pre& post dialysis measurement of weight 
Monitor HD adequacy by Kt/v 
Monitor HD adequacy by urea reduction 
ratio 
Monitor anaemia by testing HB, HCT, 
Regions 
North west 
N=21 (%) 
3 (14) 
21 (100) 
21 (100) 
3 (14) 
5 (24) 
serum ferritin and total iron binding 10 (48) 
capacity 
Monitor serum calcium and phosphorus 18 (86) 
Monitor of serum albumin 13 (62) 
Monitoring of Parathyroid hormone 3 (14) 
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North east South Total 
N=ll (%) N=8 (%) N=40 (%) 
I (9) 0(0) 4 (10) 
II (100) 8 (100) 40 (100) 
II (100) 8 (100) 40 (100) 
I (9.1) 0(0) 4 (10) 
2 (18) 0(0) 7 (18) 
5 (45) I (13) 16 (40) 
10 (91) 6 (75) 34 (85) 
7 (64) 3 (38) 23 (58) 
I (9) I (13) 5 (13) 
4. 3. 4. Infection control measures 
Facilities for isolation of patients with chronic viral infections were not available in all centres. 
All centres routinely screened patients for HBV, HCV and HIV infection every 3-6 months and 
upon transfer from another dialysis facility. Table 4. 4. shows that separate rooms were 
allocated for patients who were seropositive for chronic viral infection in 93% of the units 
while a dedicated machine/s in a common room were reserved for infectious patients in the 
remaining 7%. Vaccination against HBV was available for staff in all centres and for patients 
in 65%. Hand wash facilities were available in each HD room in 22 centres (55%). No dialyzer 
reuse was permitted in any centre despite a relative shortage of high flux dialyzers. Machine 
disinfection was performed routinely after each dialysis session in all dialysis facilities. 
Samples of water for biological quality testing had been collected during the preceding year in 
one quarter of centres. However, no analysis reports were found in any centre. Chemical 
quality of HD water was not tested in any centre. Sharps separation was routinely practiced by 
90% of dialysis centres. Facilities for treatment of hospital waste were available in only 9 
centres. 
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Table 4. 4: Description of infection control measures in dialysis centres in 
different regions of Libya. 
Regions 
North west North east South Total 
N=21 N=ll N=8 N=40 
(%) (%) (%) (%) 
Isolation of chronic viral infection sero-
reactive patients in special rooms 
18 (86) II (100) 8 (100) 37 (93) 
HBV vaccine for patients 10 (48) 9 (82) 7(88) 26 (65) 
Hands wash facility in each 
12 (57) 6 (55) 4 (50) 22 (55) 
haemodialysis room 
Water quality tests Biological 6 (29) 3 (27) 1 (13) 10 (25) 
performed during the 
preceding year Chemical 0 0 0 0 
Separation of sharps 20 (95) 10 (91) 6 (75) 36 (90) 
Waste disposal Domestic 14 (67) 10 (91) 7 (88) 31 (78) 
Incineration 7 (33) 1 (9) 1 (13) 9 (23) 
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4. 4. Discussion 
This study attempted to gather baseline information about the structure and quality of dialysis 
services in Libya in order to promote improvement and facilitate the development of a renal 
registry as well as to initiate further studies in the country. A renal registry represents a 
valuable resource for auditing services and provides regular performance feedback to dialysis 
centres as well as health care authorities (179, 223). 
This study shows for the first time, that Libya has a relatively high prevalence rate of ESKD 
patients treated with dialysis (table 4. 5). It is higher than rates reported in countries like 
Philippines, Romania, Thailand and the UK (224, 225). This rate is double the average rate 
estimated for the Mediterranean region of 312-352 pmp (24, 25). Furthermore, it is 
approximately one third higher than the rate reported in Saudi Arabia (19). The provision of 
dialysis has increased in Libya in the decades since it was introduced. The need for this service 
is expected to grow further: first, because of increasing prevalence of classical risk factors for 
ESKD in the community (190, 226), second, because of weak PHC and absence of screening 
programmes which slow the progress of CKD to ESKD (222) and third, due to limited renal 
transplantation services as Libya is exclusively dependent on the live related donors (205). 
Kidney transplantation was introduced into the country as a collaborative project between 
Poland and Libya in 1988. Polish surgeons transplanted 63 kidneys from live related donors 
during 8 years. Eventually, transplantation activities totally collapsed, largely due to United 
Nation's sanctions against Libya and subsequent shortage of the immunosuppressive therapy 
and medical equipments. Lately, in 2004, renal transplantation activates was initiated in a sole 
centre in Tripoli with a capacity of approximately 45 Iive- related renal transplants per year. 
This restricted access to renal transplantation increases dialysis dependency because most 
patients fail to provide a suitable enthusiastic relative. A deceased organ donation program has 
been initiated in the country, but is still hampered by lack of proper knowledge, religious 
misconception and other psychological factors (207). 
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Table 4. 5: Prevalence rates of dialysis per million population in different 
countries/regions. 
Country/ region 
Prevalence rates of dialysis 
Year 
per million population 
Taiwan 2288 2007 (224) 
United States 1159 2008 (224) 
Libya 624 2009 
Saudi Arabia 475 2009 (19) 
UK 411 2008 (225) 
Thailand 363 2007 (224) 
Romania 345 2007 (224) 
Mediterranean region 312- 352 2006- 2008 (24, 25) 
Bangladesh 99 2007 (224) 
Philippines 74 2007 (224) 
Although CAPD is a popular method for treating ESKD in many countries (227) there were 
only 3 centres offering CAPD which served 35 patients. The total number of active PD patients 
in the Middle East was recently estimated to be approximately 8170, representing around 
10.2% of overall dialysis population in the region (25). Most were in Turkey, Iran and Saudi 
Arabia who have well established programmes (25). 
There were wide discrepancies in the working capacity between different centres in different 
regions of Libya. Some facilities were overloaded with patients while others were running just 
a few sessions per week. Most facilities did not operate at full working capacity with each 
machine serving only 3- 4 patients per week. In contrast, most dialysis units in France (228) 
and England (229) operate at near maximal HD capacity. This observation raises the 
importance of integrated health care planning and the lack of a national standard for the 
number of dialysis stations per population. The data presented will inform decisions about 
improving dialysis infrastructure and future expansion. 
Despite the provision of modem HD machines, weak technical support especially in remote 
centres resulted in an accumulation of non-functioning HD machines (15.4% of total number 
of machines) and waste of health care resources. The deficiency was more pronounced in the 
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southern dialysis centres where 28% of machines were non- functioning. There is therefore an 
urgent need to improve technical support to dialysis centres. 
Permanent vascular access in the form of an A VF or A VG is the safest and most cost effective 
way to perform HD (59). Our data show that surgical services for creation of a fistula were 
limited to a few centres where vascular surgery staff and equipment were available. Many 
patients have to travel long distances and wait variable periods of time before getting their 
vascular access surgery. Centres in the southern region were most affected. Expansion of 
services for vascular access provision is therefore an important priority. 
All dialysis staff in Libya are recruited, paid and supervised by the Secretariat for Health and 
the Environment. Our results show an overall staffing ratio of one nephrologist! internist to 40 
patients. This ratio is greater than that reported in the United States and France (1 :48) (180, 
228) and far greater than New Zealand (I: 102) (230). The distribution of senior qualified 
nephrologists in Libya varies widely between regions. However, this number does not reflect 
the actual care delivered to dialysis patients because they are usually engaged in multiple tasks 
including nephrology outpatient clinics, dialysis follow up, inpatient care and medical 
teaching. Despite the enormous growth of the heaIthcare sector in Libya, specialised physicians 
are still deficient in certain fields including renal medicine. This deficiency might be attributed 
to defective planning of graduate educational courses on one hand and migration of qualified 
staff (brain drain) on the other (193). The 53 junior dialysis physicians identified in this study 
were new medical graduates who lack necessary knowledge and experience. These new 
physicians work in dialysis centres as a part of their general medicine training programme for a 
maximum period of 6 months. More research is required to determine the actual nephrologist-
patient contact time and dialysis patient satisfaction in order inform decisions regarding 
optimal staffing levels. Regarding nursing staff, our data show adequate nurse to patient ratios. 
As in most countries, nurses deliver most of dialysis patient care (231). Many health care 
institutes in Libya provide training programmes for dialysis nurses. Conversely, our results 
show a marked deficiency of social workers and dieticians despite their important role in 
dialysis patient care (232, 233). 
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In Libya, there are no national dialysis practice guidelines and few clinical practitioners were 
familiar with KDOQl guidelines. This lack of national guidelines has resulted in variable 
approaches to patient management and monitoring. The majority of centres rely on clinical 
monitoring and monthly pre-dialysis urea readings which probably do not reflect urea 
clearance since low values may be a sign of poor nutrition. Similar problems have been 
observed in Saudi Arabia prompting calls for guidelines to optimize dialysis delivery in that 
country (234). Online measurement of urea removal by Kt/v is available on most HD machines 
used in Libya. There is therefore the potential to substantially improve the quality of 
monitoring through national guidelines. In addition to lack of uniform standards, monitoring of 
patients was adversely affected by intermittent shortage of some laboratory reagents. Similarly, 
the supply of medication and high flux dialyzers was subjected to repeated interruption in 
almost all facilities. 
Dialysis centres in Libya generally apply a strict infection control policy including; screening 
patients for blood borne infections, liberal use of non-sterile gloves, machine disinfection, no 
dialyzer reuse, maintenance of hygiene and vaccination of staff against HBV. However, nearly 
half of facilities lacked hand washing facilities in dialysis rooms. This was either because of 
faulty design or as a result of converting rooms built for other purposes into HD rooms to 
accommodate increasing numbers of patients. Hand disinfectant was available in most HD 
rooms and was routinely used by staff. Studies are needed to determine prevalence rates of 
blood borne infections in dialysis patients as well as the rate of sero-conversion of negative 
patients to provide better data regarding the effectiveness of infection control measures. 
Separation of sharps was not practiced by 10% of Libyan dialysis centres. However, even after 
separation of sharps, the large amount of potentially infective waste generated from dialysis 
practice was mostly treated as domestic waste by dumping or open air burning. The technology 
needed for management of hospital waste is limited and should be improved. 
Libya faces strong constraints in terms of access to fresh water due to perpetual drought (235). 
Many dialysis centres were obligated to dig their own wells to maintain water supply. 
However, testing water quality was not regularly practiced despite reports about ground water 
pollution (236). All Libyan dialysis centres have water treatment plants but samples of dialysis 
water were collected from only a quarter of dialysis facilities. Even in these facilities no 
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laboratory reports were returned for feedback. Again, there were no dialysis water reference 
standards to guide practitioners. 
4. 5. Conclusion 
Dialysis (mainly HD) services are appropriately distributed to serve almost all populated 
regions and are funded by Libyan government. In spite of large geographic area, the provision 
of dialysis appears adequate but there is a wide discrepancy in methods applied to manage and 
monitor patients. Several areas for improvement have been identified including a need for more 
efficient use of existing facilities, promotion of more uniform dialysis practices by guidelines, 
improved technical support, establishment of a Renal Registry, recruitment of more 
nephrologists, enhancing infection control measures, improving reliability of distribution 
networks for dialysis and laboratory supplies as well as drugs, monitoring quality of HD water 
and the development of more cost-effective alternatives such as PD and transplantation. 
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5. Epidemiology and aetiology of dialysis-treated 
end-stage kidney disease in Libya 
5.1. Introduction 
ESKD is highly prevalent globally. It has become a major public health problem and is 
associated with considerable co-morbidity and mortality. Maintenance dialysis therapy is the 
commonest mode ofRRT and demand for this service is increasing progressively worldwide. 
Libya is a sparsely populated medium-developed country but it has a high prevalence of risk 
factors for CKD such as diabetes, hypertension and obesity (l88, 226, 237, 238). Societal, 
economic and environmental transformation have contributed to people tending to adopt a 
sedentary life (239). Attention paid by the PHC systems to combat the rising epidemic of 
chronic diseases has been inadequate (240). In contrast, Libya was among the first countries in 
the region to establish free access to maintenance dialysis therapy for patients with ESKD 
(241). Health care administrative bodies have continued to expand dialysis services in terms of 
geographic coverage and capacity to cope with increasing demand (241). Kidney 
transplantation in Libya is limited by the lack of cadaveric donors and limited availability of 
suitable living-related donors (203, 204). Thus the majority of patients with ESKD remain 
dialysis dependent. Nevertheless, data regarding the epidemiology of ESKD and dialysis 
treatment in Libya are scarce and knowledge about the spectrum of renal diseases is very 
limited. The purpose of this study was to develop the first comprehensive description of the 
epidemiology of dialysis-treated ESKD in Libya. The study was performed prior to the recent 
conflict but as Libya prepares to redevelop its healthcare system these data will be vital to 
guide strategies for the prevention ofCKD and planning for the provision ofRRT. 
5. 2. Methods 
The study was performed by a Libyan researcher with support and guidance provided by a 
Nephrology Department in the UK. First, a cross-sectional study was performed from May to 
August 2009. This included all adult maintenance dialysis facilities in Libya (n = 39), One 
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paediatric dialysis facility was excluded. All dialysis facilities belong to the public sector. 
Medical supervisors of maintenance dialysis facilities throughout the country were contacted 
by visit or phone call to be informed about the study. All agreed to participate and to cooperate 
with the research team. 
A data collection sheet was prepared and used to gather information about all currently 
registered dialysis patients in the country. Forms included data regarding date of birth, sex, 
ethnicity, nationality, type of dialysis, date of dialysis initiation and primary kidney disease. 
Date of birth was recorded if known. Otherwise, the year of birth was used. The same applied 
for the date of first dialysis. Primary kidney disease was recorded according to the opinion of 
the treating physician or medical reports when available. 
For the majority of dialysis units (n = 28), the research team collected all information by 
interviewing patients and inspecting medical records to assure quality and validity of the data. 
For remote facilities, data collection sheets were distributed to the clinical supervisor for 
completion. Frequent phone calls were used to answer queries and ensure that data were 
correctly documented. A pilot study was undertaken in 5 dialysis units that included 100 
patients (20 from each unit). Difficulties in collecting data were explored and solutions 
developed. Data were cross checked for patients who were known to receiving dialysis in 
another centre within the country. Patients who were absent at the time of the study for a 
period of less than one month for travel in or outside the country were included among the 
prevalent population. Analyses performed included all adult patients prevalent on dialysis on 
30 August 2009. 
Population estimates were obtained from the Libyan national statistics department. The age and 
gender breakdown of the population in each region was obtained from mid-2009 popUlation 
estimates based on 2006 census data. The number of dialysis patients was calculated for the 
country as a whole. In order to investigate geographic variation in the epidemiology of ESKD, 
data were also grouped into 3 main geographic regions. 
The second stage of the study was a prospective collection of information about all new 
patients who started dialysis from September 2009 to August 2010. Variables collected were 
identical to that used during the cross-sectional study and the same data forms were used. The 
69 
research team conducted data collection frequently during the year to ensure the inclusion of 
every new patient in the country. Subsequently, researchers conducted field visits to dialysis 
facilities from August to December 2010 to validate the information. 
Data are presented as mean± standard deviation if normally distributed or median (interquartile 
range) if not. A Chi-squared test was used to compare frequencies between groups. A p-value 
of <0.05 was considered statistically significant. Analysis was performed by using SPSS 
version 16.0. 
Permission to conduct the study was granted by the Ministry of Health. Ethical approval for the 
research was obtained from the Libyan National Committee for Bioethics and Bio-safety. 
Patients each gave written informed consent. 
5. 3. Results 
5. 3. 1. Prevalence of ESKD in Libya 
As shown in Table 5. 1, the total number of adult ESKD patients undergoing maintenance 
dialysis therapy in Libya was 2417 in August 2009. The estimated adult population of Libya 
during 2009 was 3,873,000, giving a prevalence of dialysis-treated ESKD of approximately 
624 pmp. The prevalence rate varied slightly by region with the highest rate of 628 pmp in 
North West region, the most populated area of the country. Most prevalent patients were under 
65 years of age (85%). Female patients tended to be older than males, except in the south. 
Duration of dialysis was a median of 3 years and tended to be higher in females (Table 5. 2). 
The majority of dialysis patients were Libyan nationals (97.8% of prevalent and 96.6% of 
incident patients). 
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Table 5. 1: Prevalent and incident dialysis patient numbers and rates for Libya 
and its regions 
Whole 
Regions 
country 
North West North East South 
Number of prevalent patients 2009 1558 653 206 2417 
Prevalence rate 2009 (pmp) 628 623 597 624 
Number of incident patients 2010 593 287 213 1093 
Incidence rate 2010 (pmp) 239 274 617 282 
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Table 5. 2: Age, age at onset and dialysis vintage for prevalent and incident 
dialysis patients in Libya and its regions. Data are median and interquartile 
range 
Region Total 
North West North East South 
(n = 1558) (n = 653) (n = 206) 
Age of prevalent Male 49 46 49 48 49 
patients in years 36-61 35-59 36-61.3 36-61 36-61 
Female 49 50.5 42.5 49 
(n =2417) 
34-60 37-61 32.3-59 35-61 
Age at onset of dialysis Male 45 42 47 44 45 
(n =2417) 31-58 28-55 31-59.9 30-58 30-58 
Female 45 46 38 45 
30-57 31-57 27-57.8 30-57 
Dialysis vintage in years Male 3 3 2 2.5 3 
(n = 2417) 1-6 1-7 0.1-4 1-6 1-6 
Female 3 3 2 3 
1-5 1-6 2-2 1-6 
Age of incident patients Male 50 47 46 48 49 
in years (n = 1093) 37-63 34-61 30-57 35-61 35-62 
Female 52 53 43 50 
35-66 41-64 36-54 36-64 
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Figure 5. 1, shows that the prevalence of dialysis-treated ESKD was higher among males 
versus females at all ages. Overall, males represented 58% of prevalent dialysis population. 
The prevalence of ESKD varied considerably with age. Prevalence rates were low in young 
adults but showed a steady increase with age. Prevalence rates peaked in the 55-64 year age 
group at 2475 pmp for males and 2197 pmp for females. After age 74 years there was a sharp 
decline in prevalence and very few patients were over 85 years. Most prevalent patients on 
dialysis were white ethnicity (87%). However, ethnic distribution varied between regions with 
the highest black to white ratio of 1.9 to 1 in the South. 
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Figure 5.1: Prevalence rate pmp of dialysis-treated ESKD in Libya for males and 
females by age group (males and females are a proportion of the gender specific 
in a million population) 
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5. 3. 2. Incidence of ESKD in Libya 
A total of 1093 new patients started dialysis during the I-year observation period, giving an 
incidence rate of 282 pmp. Incidence rates varied between regions with a substantially higher 
rate observed in the South (Table 5. 1). In most age groups the incidence rate was higher in 
males than females (figure 5. 2). The incidence rate increased with age until it peaked in those 
aged 65-74 years and decreased sharply beyond age 75 years. Incident female patients were 
slightly older than male patients. Most incident patients on dialysis were white (80.9%). 
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Figure 5. 2: Incidence rate pmp of dialysis-treated ESKD in Libya for males and 
females by age group (males and females are a proportion of the gender specific 
in a million population) 
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5. 3. 3. Aetiology of ESKD in Libya 
Information about primary kidney disease was complete for all prevalent dialysis patients but 
was missing in 75 (6.9%) of incident dialysis patients. Data are shown in tables 5. 3 and 5. 4. 
The most common cause of ESKD among prevalent and incident patients was diabetes. The 
frequency of different categories of pathology was similar for prevalent and incident patients. 
Diabetes and hypertensive nephropathy were more common as causes of ESKD in patients 
aged 50 years or older whereas glomerulonephritis and hereditary diseases were more common 
in those aged under 50 years. Autoimmune diseases accounted for only a small proportion of 
all ESKD and were more common among females. 
Table 5. 3: Aetiology of primary kidney disease of prevalent dialysis patients 
according to gender and age 
All 
Primary kidney disease Gender Age 
patients 
Female (n <50 years ~ 5 0 0 years 
Male (n = 1402) (n=2417) 
1015) (n = 1268) (n = 1149) 
Diabetic Nephropathy 396 (28.2)* 245 (24.1) 169 (13.3)* 472 (41.1) 641 (26.5) 
Hypertensive Nephropathy 180 (12.8) * 173 (17) 129 (10.2)* 224 (19.5) 353 (14.6) 
Glomerulonephritis 318 (22.7) * 194(19.1) 413 (32.6)* 99 (8.6) 512 (21.2) 
Interstitial Nephritis 14 (I) 15(1.5) 17 (1.3) 12 (I) 29 (1.2) 
Obstructive Nephritis 78 (5.6) 42 (4.1) 59 (4.7) 61 (5.3) 120 (5) 
Chronic pyelonephritis 19(1.4)* 29 (2.9) 33 (2.6) * 15(1.3) 48 (2) 
Polycystic kidney disease 82 (5.8) 70 (6.9) 68 (5.4) 84 (7.3) 152 (6.3) 
Congenital and hereditary diseases 168(12)* 130 (12.8) 220 (17.3)* 78 (6.8) 298 (12.3) 
Autoimmune diseases 4 (0.3) * 13(1.3) 16 (1.3) * 1(0.1) 17 (0.7) 
Other 39 (2.8) 32 (3.2) 48 (3.8) * 23 (2) 71 (2.9) 
Unknown 104 (7.4) 72 (7.1) 96 (7.6) 80 (7) 176 (7.3) 
Data are number (percent) 
*p < 0.05 versus comparison group 
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Table 5. 4: Aetiology of primary kidney disease of incident dialysis patients 
according to gender and age 
All 
Primary Kidney Disease Gender Age 
patients 
Male Female <50 years 2:50 years 
(n = 1018) 
(n = 621) (n = 397) (n = 521) (n =497) 
Diabetic Nephropathy 173 (27.9) 116 (29.2) 90(17.3)* 199(40) 289 (28.4) 
Hypertensive Nephropathy 101 (16.3) 60 (15.1) 29 (5.6)* 132 (26.6) 161 (15.8) 
Glomerulonephritis 133 (21.4) 71 (17.9) 173(33.2)* 31 (6.2) 204 (20) 
Interstitial Nephritis 7 (1.1)* 17(4.3) 14 (2.7) JO (2) 24 (2.4) 
Obstructive Nephritis 53 (8.5)" 6 (1.5) 17 (3.3)* 42 (8.5) 59 (5.8) 
Chronic pyelonephritis 9 (1.4) 4 (I) 0(0)* 13 (2.6) 13 (1.3) 
Polycystic kidney disease 13(2.1)* 41 (10.3) 31 (6) 23 (4.6) 54 (5.3) 
Congenital and hereditary diseases 42 (6.8) 40 (10.1) 73 (14)" 9 (1.8) 82 (8.1) 
Autoimmune diseases 4 (0.6)" 10 (2.5) I 1(2.1)" 3 (0.6) 14 (1.4) 
Other 10 (1.6) 4 (I) 10(1.9) 4 (0.8) 14 (1.4) 
Unknown 76 (12.2)* 28 (7.1) 73 (14)* 31 (6.2) 104 (10.2) 
Data are number (percent) 
*p < 0.05 versus comparison group 
5. 4. Discussion 
This study represents the first comprehensive description of the epidemiology of dialysis-
treated ESKD in Libya. Our study shows a prevalence rate for ESKD markedly higher than 
rates estimated for the Mediterranean region of 312 to 352 pmp (24, 25) despite similar 
demographic and socioeconomic characteristics between Libya and neighbouring countries. 
Libya's prevalence rate is also higher than rates reported from individual countries in the region 
like Saudi Arabia (475 pmp) (19), EI-Minia city in Egypt (208 pmp) (26), Kuwait (240 pmp) 
(24) and Oman (220 pmp) (24). Reasons for the high prevalence rate in Libya might include a 
high prevalence of CKD in the population and limited access to renal transplantation (204, 
242). The high incidence rate of ESKD observed in this study (282 pmp) supports the notion 
that CKD is an important health problem in Libya that requires urgent attention. The rate is 
76 
more than double that observed in European countries such as Austria (131 pmp) (243) and 
Denmark (129 pmp) (243) despite the fact that the Libyan population is younger than that of 
most European countries. Moreover, the incidence rate observed in Libya is even higher than 
rates reported in other places with young populations such as Qatar (202 pmp) (16), Tunisia 
(159 pmp) (17), Bhopal city in India (151 pmp) (18), Malaysia (138 pmp) (244), Saudi Arabia 
(122 pmp) (19), Jordan (III pmp) (20) and Aleppo city in Syria (60 pmp) (21). Whereas the 
prevalence rate did not vary by much in the different geographic regions of Libya the observed 
incidence rate was substantially higher in the South. Regional variation in incidence of ESKD 
has been reported by other authors (185, 245). The reasons for this variation in Libya require 
further investigation and have important implications for future healthcare provision. The 
South of Libya is a remote, sparsely populated and deprived area. It is also hot and dry and is 
inhabited by a mixture of different minorities such as black Arabs, Tuareg and Tebou tribes. 
Thus geographic, racial and socioeconomic factors may all be relevant. It is also notable that 
the proportion of new patients who commenced dialysis therapy in one year represents 45% of 
the number of prevalent dialysis patients in Libya. Moreover in the South the incidence rate 
was triple the prevalence rate. Possible explanations for these observations include a high 
mortality rate on dialysis or rapidly increasing incidence of ESKD. Both possibilities require 
urgent investigation and have serious implications for future demand for dialysis in Libya. 
The median age of prevalent patients revealed by this study was substantially lower than that 
observed in other countries including the UK (65.9 years for HD and 61.2 years for PO) (246), 
United States (59.1 years) (224), Iceland (64.4 years), Austria (60.1 years), Denmark (58.8 
years) and Greece (58.1 years) (243). The majority of patients with ESKD in Libya are of 
economically active age and ESKD therefore has a significant impact on families and society. 
The observed median age for incident patients in Libya (49 years) was considerably lower than 
the UK (64.8 years) (12). Consistent with studies from most other countries, males 
outnumbered females in the prevalent and incident populations (224, 247, 248). Nevertheless, 
the median age of incident females in the South was a decade younger than females in other 
regions of the country. This wide range of age presentation in the South might reflect gender 
inequity, health care deficiency and environmental factors. 
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Like many other countries diabetic nephropathy was the leading cause of ESKD in both 
prevalent and incident dialysis populations and was significantly more common among older 
patients. Generally, the prevalence of diabetes in Middle East region is high according to the 
International Diabetes Federation (249, 250). Reasons include increasing urbanisation, aging of 
the population, increasing obesity and falling levels of physical activity (251, 252). Efforts to 
reduce the burden of ESKD in Libya should therefore focus on measures to reduce incidence of 
type 2 diabetes mellitus (55, 253) through public awareness, screening and promotion of a 
healthy lifestyle as well as prevention of microvascular complications in those with diabetes 
(254). Glomerulonephritis was the second most frequent cause of ESKD in Libya in prevalent 
and incident cases and was significantly more common among young and male patients. The 
observed proportion is midway between very high levels reported from countries like China 
and Kuwait of approximately 35% (43, 44), Costa Rica (30%) (45) and Yemen (25%) (46) and 
lower prevalence observed in countries like Qatar (13%) (16), Sri Lanka (12%) (47) and 
Pakistan (10%) (48). Reasons for the high prevalence of glomerulonephritis require further 
investigation, which is hampered by the shortage offacilities able to perform renal biopsies and 
histology. A substantial proportion of ESKD was attributed to hypertension but it is unclear 
what proportion of this represented hypertension secondary to primary renal disease. 
Congenital and hereditary kidney disease accounted for a significant minority of ESKD in both 
prevalent and incident patients. This is likely due to the high rate of marriages between 
relatives, especially first cousins, in Arab communities (52, 255, 256) including Libya. A 
shortage genetic diagnostics and counselling is a major contributor to this problem. In 
summary, despite Libya's unique social and demographic features the observed causes of 
ESKD are similar to that described in most other countries, though the contribution of 
glomerulonephritis and hereditary kidney disease is greater than in many developed countries. 
It is therefore likely that interventions that have proved successful in reducing the incidence of 
ESKD in other countries such as early detection of CKD, treatment of hypertension with 
angiotensin-converting enzyme inhibitors and prevention or treatment of diabetes are likely to 
be effective in Libya too. 
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Strengths of this study are the inclusion of all current dialysis units in the country to ensure 
collection of the most complete data possible and prospective capture of data regarding new 
patients commencing dialysis. Limitations include reliance on limited and partially incomplete 
medical records and lack of histology to confirm the cause of ESKD in the majority of cases. 
We have described the epidemiology of ESKD among patients receiving dialysis but there are 
no data regarding patients with ESKD who died without the benefit of dialysis. It is therefore 
likely that the true incidence of ESKD is higher than what we have observed. Further research 
is required to investigate how many patients with ESKD are not offered dialysis and the 
reasons for this. 
5. 5. Conclusions 
In conclusion we report for the first time high prevalence and incidence rates of dialysis-treated 
ESKD in Libya. The relatively young age of those affected emphasizes the need for urgent 
measures to reduce the incidence of CKD and its progression. Emphasis should be placed in 
the first instance on the prevention and treatment of diabetes and hypertension. Further 
research is required to investigate the high incidence of glomerulonephritis. As Libya rebuilds 
its heaIthcare system following the recent conflict it is hoped that the prevention of ESKD will 
constitute an important priority and that the data presented will inform the strategies required. 
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6. Hepatitis Band C infection in haemodialysis 
patients in Libya: Prevalence, Incidence and Risk 
Factors 
6. 1. Introduction 
Chronic infections with HBV and HCV are associated with serious health risks due to hepatic 
cirrhosis and hepatocellular carcinoma. Patients receiving maintenance HD therapy are at 
increased risk for acquiring these infections and have a higher prevalence of HBV and HCV 
than the general population (117, liS). Prior to effective screening of blood donations, HCV 
infection was associated with blood transfusions needed to correct the anaemia associated with 
kidney disease (257, 25S) but patient to patient transmission in HD units is also reported (259, 
260). HBV infection is usually due to patient to patient transmission within HD units (261). 
Recognition of the risk of nosocomial infection has resulted in recommendations that strict 
infection control procedures should be followed on HD units; patients with blood-bourne virus 
infections should be isolated from sero-negative patients during dialysis and patients as well as 
staff should be vaccinated against HBV (262, 263). The introduction of blood donor screening 
and a reduction in blood transfusions due to the availability of recombinant erythropoietin has 
significantly reduced the incidence of new HCV infections among HD patients in many 
countries (264-266). 
Libya provides free access to maintenance HD for ESKD through a rapidly expanding network 
of centres. Although there are no national dialysis practice guidelines or infection control 
polices enforced by health care authorities, there is general agreement that patients on HD 
should be screened for HBV and HCV infection before the initiation of HD and monitored 
every 3-6 months thereafter (241). Sero-positive patients are dialysed on dedicated machines 
either in an isolated area or alongside sero-negative patients if space does not allow isolation 
(241). A national serological survey for HBV and HCV infections among the general 
population was performed in Libya during 2003 and revealed prevalences of 2.2% and 1.2% 
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for HBY and HCY, respectively (267). Other local surveys reported that the rate of HBsAg 
positivity among blood donors ranged from 1.3% to 4.6% (268), while the rate of HCY 
antibodies was 1.2% (269). Global data indicate that the prevalence of HBY and HCY 
infection is high in populations of Africa and the Middle Eastern regions (I 19- I 21). HCY 
infection was estimated by World Health Organisation to affect 4.6% of the Eastern 
Mediterranean population and 5.3% of the population of Africa (270). This study aimed to 
investigate for the first time the incidence and prevalence of HBY and HCY infection in the 
entire HD population of Libya. 
6.2. Methods 
This descriptive study was carried out in all HD centres treating adult patients in Libya (n=39) 
from May 2009 to December 20 I O. One dialysis facility was excluded because it provided 
dialysis only to paediatric patients. Phase I of the study was a collection of cross-sectional data 
regarding all adult patients in maintenance HD facilities (n=2382). Large and medium capacity 
HD facilities were visited by the researchers in order to collect data. Patient records were used 
to obtain patients' age, gender, time on HD, medical history, sero-positivity to HBY and HCY 
as well as other laboratory results. Sero-positivity to HBY was defined by detection of HBsAg 
and sero-positivity to HCY by detection ofanti-HCY antibodies by a third generation enzyme-
linked immunosorbent assay (ELISA). ELISA tests were performed in local laboratories. In 
addition, 1732 patients from 24 centres were interviewed regarding other potential risk factors 
for HBY and HCY infection. These included history of blood transfusions and history ofHD in 
another centre within Libya or abroad. Data was also obtained regarding infection control 
procedures at each HD facility. For small and remote facilities, data collection forms were 
posted to clinical supervisors who were requested to collect information about their patients. 
They were contacted frequently by phone to deal with any queries related to the required 
variables. Forms were returned within 30 days. 
Phase II of the study was to prospectively detect sero-conversion to HBY or HCY in 
previously sero-negative HD patients during I year of follow-up. This step included a cohort of 
1160 patients from 35 centres (four centres were excluded because of incomplete information). 
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All sero-conversions were recorded and included even if patient was transplanted or died 
afterwards. The research team frequently monitored HD patients during the year to assure the 
inclusion of every new sero-conversion. All new sero-conversions were retested to confirm the 
positive result. Field visits were repeated at the end of I year to validate the information. 
Data are presented as mean±SD if normally distributed or median (interquartile range) if not. 
Analysis was performed using SPSS version 16.0. A Chi-square test was used to compare 
frequencies between groups. Correlations were tested with a Pearson's test. A t-test was used 
to compare means between groups for data with normal distribution or Mann-Whitney test for 
non-parametric data 
Permission to conduct the study was granted from the ministry of health. The project was 
approved by the Libyan National Committee for Bioethics and Bio-safety. Patients gave 
written informed consent to be interviewed. The study was performed by a Libyan researcher 
with support from a Nephrology Department in the United Kingdom. 
6. 3. Results 
The median age of adult HD patients included was 49 years (range 36-61 years) and 58% were 
male. A total of 831 patients (34.9%) were sero-positive for HBV and/or HCV. The majority of 
infected patients were positive for anti-HCV antibodies (31.1 %) and 2.6% were HBsAg 
positive. Twenty-eight patients (1.2%) had mixed infection with HBV and HCV (Table 6. I). 
Of the sero-positive patients 4.7% were known to be infected before the initiation of HD. 
OveralI the prevalence of sero-positivity was similar among males and females (35.8% versus 
33.7%, respectively) but males comprised a greater proportion of those with HBV or combined 
infection (Table 6. I; P=O.O I for comparison between groups). 
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TabJe 6.1: Frequency, age and gender distribution of HBV and/or HeV sero-
positive haemodiaJysis patients. Data are number (percent) or median 
(interquartiJe range) 
HBV HCV HBV+HCV Total 
n=62 0=741 0=28 0=831 
Male 45 (72.6%) 427 (57.6%) 22 (78.6%) 494 (59%) 
Frequency 
Female 17 (27.4%) 314 (42.4%) 6 (21.4%) 337 (41%) 
Male 49 (33-58) 46 (36-59) 40 (31-45) 46 (36-59) 
Age (years) 
Female 44 (33-61) 48 (34-59) 44 (42-54) 47 (35-59) 
The prevalence of HBV and/or HCV infection varied widely between HD centres from 0% to 
75.9%. Four centres had no sero-positive patients and half of centres were free from HBV 
infection. Patients' sero-positive for both viruses were found in 28.2% of centres (figure 6.1). 
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Figure 6. 1: Prevalence of HBV and/or HeV sero-positivity in different 
haemodialysis centres in Libya 
Univariate analysis of potential risk factors for infection with HBY and/or Hey was performed 
by comparing infected and non-infected patients (Table 6. 2). Sero-positive patients were 
younger and had been receiving dialysis for substantially longer. History and number of blood 
transfusions was also significantly associated with sero-positivity. Mean values for alanine 
aminotransferase and aspartate aminotransferase were higher in sero-positive patients despite 
being within the normal range. 
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Table 6. 2: Factors potentially associated with HBV and/or HeV infection in 
haemodialysis centres in Libya 
Factors potentially 
associated with HBV±HCV 
infection 
Age in years (mean± SO) 
Males (number and percent) 
Whites (number and percent) 
Dialysis vintage in years (median and 
IQR) 
Previous blood transfusion (number 
and percent) 
Number of blood transfusions 
(median and IQR) 
Previous renal transplant (number 
and percent) 
Previous dialysis abroad (number and 
percent) 
Previous dialysis in another Libyan 
centre (number and percent) 
Haemoglobin level in gldl (mean± 
SO) 
Alanine Aminotransferase in lUlL 
(mean± SO) 
Aspartate Aminotransferase in lUlL 
(mean± SO) 
Diabetes (number and percent) 
Erythropoietin treatment (number and 
percent) 
Sero-positive N=83 J 
Number* Value 
83 1 47. 1± 14.4 
83 1 494 (59.4%) 
805 718 (89.2%) 
83 1 6(3- 10) 
597 482 (80.7%) 
597 2 (I -3) 
822 11 5 (14.0%) 
617 376 (60.9%) 
612 324 (52.9%) 
83 1 10.2± 1.9 
269 27.8± 20.2 
232 29.6±2 I. I 
83 1 195 (23.5%) 
604 450 (74.5%) 
*Number of patients with valid data for each variable 
IQR: interquartile range 
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Sero-negative N=J55J 
p- value 
Number* Value 
155 1 49.5± 16.2 <0.001 
1551 887 (57.2%) 0.296 
1528 1312 (85 .9%) 0.023 
1551 2(0.1-3) <0.00 1 
1010 688 (68.1%) <0.001 
1010 I (0-3) <0.00 1 
1533 41 (2.7%) <0.001 
1025 540 (52.7%) 0.001 
1018 447 (43.9%) <0.001 
155 1 9.7± 1.8 <0.00 1 
353 19.6± 17.9 <0.001 
328 21.3±20.3 <0.001 
1551 55 1 (35.5%) <0.00 1 
1059 830 (78.4%) 0.071 
Results of the prospective study showed that 89 of 1160 (7.7%) previously sero-negative 
patients sero-converted during 1 year. The majority (82 patients) developed anti-HCV 
antibodies (incidence 7.1 %). Seven patients became positive for HBsAg (incidence 0.6%). Age 
and gender distribution of those who sero-converted is shown in Table 6. 3. 
Table 6. 3: Frequency, age and gender distribution of patients who sero-
converted during 1 year of follow-up. Data are number (percent) or median 
(interquartile range) 
HBV HCV Total 
n=7 n=82 n=89 
Male 5 (71.4%) 49 (59.8%) 54 (61 %) 
Frequency 
Female 2 (28.6%) 33 (40.2%) 35 (39%) 
Male 50 (35-67) 50 (38-64) 50 (38-64) 
Age (years) 
Female 57 (40-73) 52 (44-64) 52 (43-65) 
Figure 6. 2. shows wide variation in rates of newly acquired infections between different 
dialysis centres. No sero-conversion was found in two small-capacity centres (one treating 2 
patients and the other, 5 patients). New HBsAg positive cases were detected in 4 centres in 3.3-
10.3% of previously negative patients. All new HBV cases were referred from centres already 
treating HBV infected patients. New HCV infections were reported in most centres (33 of 35) 
but the rate of HCV sero-conversion varied widely from 1.5% to 31 % of patients. Most of the 
centres with HCV sero-conversions (31/33) were providing HD treatment to previously HCV-
infected patients. However, anti-HCV antibodies were discovered in 9 patients (31 %) in a 
centre which was previously treating exclusively sero-negative patients (coded CG). Two other 
HCV sero-conversions occurred in another previously sero-negative HD centre (coded BE). 
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Figure 6. 2: Incidence of new HBV or HeV infections in haemodialysis patients 
during a 1-year follow up period 
There were no correlations between number of HD patients treated in each centre and the 
prevalence or incidence of sero-positivity to HBY or Hey. There was no difference in 
prevalence or incidence of HBY or Hey infection between units that: routinely practiced 
isolation of sero-positive patients versuS those that did not; units with hand washing facilities 
in each cubicle versus not and units that had adequate facilities for sharps disposal versus not. 
Analysis of possible risk factors for new HBY or Hey infections is shown in Table 4. Only 
duration of dialysis, history of previous renal transplant and history of receiving HD in another 
centre in Libya were significantly different between patients who sero-converted and those 
who remained sero-negative. 
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Table 6. 4: Factors potentially associated with new HBV or HeV infection in 
haemodialysis centres 
Sero-converted Stayed sero-negative 
N=89 N=1071 
Factors potentially associated with p- " Blue 
new HBV±HCV infection N umber* 
Value umber* Value 
Age in years (mean± SD) 89 50.9± 15.8 1071 50± 16.6 0.635 
Males (number and percent) 89 54 (60.7%) 107 1 613 (57.2%) 0.528 
Whites (number and percent) 89 75 (84.3%) 1056 927 (87.8%) 0.335 
Dialysis vintage in years (rnean± SD) 89 4.1± 4.4 107 1 2.2± 2.6 0.00 1 
Previous blood transfu sion (number and 
45 34 (75 .6%) 716 48 1 (67.2%) 0.244 
percent) 
Number of blood transfusions (mean± SD) 45 3.6± 6.9 716 1.8± 2.6 0.083 
Previous renal transplant (number and 
89 6 (6.7%) 1064 28 (2.6%) 0.028 
percent) 
Previous dialysis abroad (number and 
48 27 (56.3%) 714 395 (55.3%) 0.900 
percent) 
Previous dialysis in another Libyan centre 
48 31 (64.6%) 707 371(52.5%) 0.023 
(number and percent) 
Haemoglobin level in g/dl (mean± SD) 89 9.9±2. 1 1071 9.6± 1.8 0.220 
Alanine Aminotransferase in lUlL (mean± 
27 2 1.9± 22.7 274 18.6± 17.8 0.272 
SD) 
Aspartate Aminotransferase in lUlL (mean± 
24 23± 23.8 252 20.8± 2 1.2 0.925 
SD) 
Diabetes (number and percent) 89 35 (39.3%) 1071 385 (35 .9%) 0.524 
Erythropoietin treatment (number and 
51 7 ( 13.7%) 729 100 (13.7%) 0.999 
percent) 
*Number of patients with valid data for each variable 
6. 4. Discussion 
The prevalence of anti-HCY antibodies in patie nts receiving HD (31.1 % ) was re markably hig h 
and is approximately 25 times hig her than in the general population (267). It is also hig her than 
the prevalence of20.5% reported by Daw et al in a sample of200 HD patients in 200 I in Libya 
(269). Globally the prevalence of HCY among patients receiving HD varies from as low as 
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6.1% in Germany (1 26) to as high as 76% in Casablanca (127). In general, North Africa and 
the Middle East are high prevalence areas both in the general population and in HD patients 
(270). Previous studies from the region have reported a prevalence of anti-HCV antibodies in 
HD patients of 50% in Saudi Arabia (128), 42% in Tunisia (129), 20.2% in Turkey (130) and 
21 % in Jordan (20). In contrast, the observed prevalence of HBV infection (2.6%) is similar to 
the general population and similar to that reported in HD patients in other regions including 
Europe (4 .1 %), Japan (2.2%) and the United States (2.4%) (247). A study sample from the 
DOPPS that included 8615 adult HD patients from 308 dialysis facilities in Western Europe 
and the United States, reported prevalence rates for HBV infection ranging from 0% to 6.6% 
(122). Studies from less developed countries estimated that the proportion of HBsAg carriers in 
the HD population varies from 2% to 20% (271-274). According to the 2008 Saudi Centre for 
Organ Transplantation report, HBV sero-positivity was 4.6% in the Saudi HD population (19) 
while among Jordanian HD patients it was 5.9% (125). In general , the prevalence and 
incidence of HBV and HCV infections in HD patients reflects the prevalence of these 
infections in the general population, the quality of health care services in a community and the 
standards of infection control practices in HD units. The importance of HBV and HCV as a 
health risk in patients on HD is illustrated by our observation that 3% of deaths in Libyan HD 
patients during a I year observation period were due to liver failure and that 13 of the 14 
patients who died of liver failure were sero-positive for HCV and/or HBV. 
Our data show that sero-positive patients were significantly younger on average than sero-
negative patients. This observation is in agreement with a previous report from Libya showing 
that the highest prevalence of HCV antibodies was observed in HD patients aged 36-55 years 
(269). Other studies (122, 275, 276) have reported a higher prevalence of HBV or HCV sero-
positivity in older patients and the reason for this difference in not clear. On the other hand the 
prevalence and incidence of HBV or HCV sero-positivity was significantly related to the 
length of time on HD. This is consistent with nosocomial transmission related to dialysis since 
longer duration of dialysis represents a longer period at risk of acquiring an infection. Similar 
observations have been reported by other authors (131-134). Prevention of nosocomial 
transmission is of vital importance in Libya as HCV antiviral treatment is expensive and its 
availability is limited to only a few centres. 
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A positive history of blood transfusions as well as the number of blood transfusions was 
strongly associated with HBY or Hey infection at baseline, but not with new infections. Prior 
to the introduction of effective screening of blood donors, blood transfusions were recognised 
as the leading source of Hey infection and some of these infections may have been acquired 
before adequate screening was introduced (126, 131). In addition it is possible that some blood 
donors with Hey infection are being missed by current screening procedures and these may 
need to be reassessed (277, 278). On the other hand the lack of association between blood 
transfusions and new infections suggests that fewer infections are acquired by this route than 
previously. A large proportion of patients had previously received blood transfusions. The risk 
of infection could therefore be further reduced by more effective management of anaemia with 
iron supplementation and erythropoietin. In accordance with other studies (134-136), HBY or 
Hey infection was more prevalent in patients with a history of previous renal transplant. 
Infection in these patients might have been transmitted from an infected donor kidney or blood 
transfused peri-operatively. This observation emphasizes the need for adequate screening of 
potential kidney donors, which is deficient in some countries. The shortage of donated kidneys 
in Libya induces many patients to seek a transplant abroad. 
Another concern raised by the current study is that HBY or Hey infection was associated with 
a history of HD in another centre either in Libya or abroad. Many patients travel for social 
reasons but some also transfer to a maintenance HD centre after initiating dialysis as an 
emergency in a specialised centre providing acute services or may travel to another centre for 
surgery to create an A YF (241). The association of hepatitis virus infection with travel suggests 
that the risk of nosocomial infection varies between dialysis centres within Libya and abroad. 
The former is confirmed by our data showing a marked variation in both prevalence and 
incidence of HBY and Hey infection among Libyan HD units (figures I and 2). These 
observations emphasize the importance of isolating patients following their return and 
monitoring them for sero-conversion. 
Prospective follow up of sero-negative HD patients enabled us to verify 89 sero-conversions 
for HBY or Hey during I year, giving an overall incidence of 7.7% for new infections. The 
incidence rate of 0.6% for HBsAg sero-conversion is similar to that reported in Europe, Japan 
and the United States (0.4- 1.8 per \00 patient-years) (122). Three new HBsAg positive patients 
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were detected in a single centre that was treating 20 other HBsAg positive patients and 2 new 
cases were detected in another centre that was treating 14 HBsAg positive patients, suggesting 
that nosocomial transmission probably occurred. We observed a high incidence of new HCY 
infections during the I-year observation period (7.2%). The reported incidence of new HCY 
infections varies considerably between countries. A rate as low as 0.4% was observed in 
France from 1997 to 2000 (279) but higher rates have been reported from the Mediterranean 
region. According to the 2008 Saudi Centre for Organ Transplantation report, the annual rate 
of HCY sero-conversion in Saudi HD patients was 7-9% (19) while in Jordan it was 2.6% (20). 
In our study most new cases were observed in centres treating other patients with HCY 
infection, suggesting nosocomial transmission. Interestingly 9 new HCY infections were 
observed in one unit and 2 in another that previously accepted only patients without HCY 
infection. This raises the possibility of transmission from a carrier that was not detected by 
current screening procedures. 
A striking observation from this study is the wide variation in incidence and prevalence of 
HBY and HCY infections among different HD units (figures I and 2). Interestingly none of the 
potential centre-related factors that we assessed formally explained this variation. On the other 
hand, we observed variations in other practices that may be relevant. Most facilities faced a 
problem of increasing number of patients and most of them responded by adding more HD 
stations at expense of space and staff. Infection control precautions also varied widely between 
centres. They were strictly enforced in some places but frequently breached in others. This 
seemed to depend on staff initiative rather than national guidelines. On the other hand, dialyser 
reuse was not permitted and all bloodlines as well as other consumables were disposed after a 
single use (241). Some brands of HD machines were equipped with a sphygmomanometer. 
Otherwise, most non- disposable instruments used in HD environment were shared between 
sero-positive and sero-negative patients. The use of multi-dose vials of heparin was common 
and is likely to have been an important cause of nosocomial infections. Many patients started 
HD without being vaccinated against HBY. Even in vaccinated patients the antibody titre was 
not assessed. The wide variation in HBY and HCY prevalence and incidence between dialysis 
centres implies that there is potential to reduce blood-borne virus infection by transferring best 
practice from HD centres with low infection rates. In particular infection control procedures 
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should be investigated in centres with high infection rates and the use of multidose heparin 
vials must be stopped urgently. Previous studies from the region show that with appropriate 
intervention HeV infection rates in HD centres may be substantially improved. For example in 
Iran, HeV prevalence reduced from 14.4% in 1999 to 4.5% in 2006 (280) and in Saudi Arabia 
from 2.4% in 2001 to 0.2% in 2005 (281). 
Several limitations of this study should be conceded. Medical records were often incomplete 
and additional clinical information was frequently obtained by interviewing staff and patients. 
Serological testing was done in local laboratories and it is likely that there was some variation 
in the quality of testing. Testing for HeV relied on a third generation ELISA to detect anti-
HeV antibodies and confirmation or genotyping by polymerase chain reaction (peR) is 
currently not available in most centres. 
6. 5. Conclusion 
Patients on maintenance HD in Libya have a high incidence and prevalence of HeV infection 
and lower rates of HBV infection. The factors associated with HBV and HeV infection are 
highly suggestive of nosocomial transmission within HD units. Urgent action is required to 
improve infection control measures in HD centres and to reduce dependence on blood 
transfusions for the treatment of anaemia. The data presented were obtained before the recent 
conflict in Libya. It is possible that disruption of services due to the conflict may have 
exacerbated the problem of hepatitis virus infection in HD patients. 
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7. Vascular access in patients receiving 
haemodialysis in Libya 
7. 1. Introduction 
Creating and maintaining an adequate vascular access in patients receiving HD remains a 
major challenge facing dialysis providers worldwide. A native A VF represents the optimal 
form of vascular access because it affords superior blood flow as well as lower morbidity and 
mortality as compared to CVC (89, 91, 282-285). The updated NKF/KDOQI guidelines have 
strongly recommended the use of A VFs as the vascular access of first choice for HD or A VGs 
if a native A VF cannot be achieved to limit the use of CVCs to a minimum (93). Initiation of 
HD with an A VF is associated with improved survival but this is often difficult to achieve 
because it depends on mUltiple factors including adequate preparation time at pre-dialysis 
follow up (149, 286), availability of surgeons with the necessary competencies and adequate 
facilities for performing the surgery (149, 287, 288). Several patient factors also affect the 
success rates of vascular access surgery including age, gender, diabetes, peripheral vascular 
diseases and obesity (9\, \49,289-291). Thus the pattern of vascular access use varies widely 
in different HD populations. A high prevalence of A VF utilisation is reported in Europe (10) 
and Australia (93) whereas it was as low as approximately 30% in the United States during 
1990s but rose to 47% by 2007 in part due to the "Fistula First Breakthrough Initiatives" (4, 
285, 292). A second challenge to maintaining a high prevalence of permanent vascular access 
is loss of A VF or A VG due to dysfunction. Many patients require more than one A VF during 
their time on HD treatment and rates of intervention vary between different HD populations. 
Dysfunction occurs due to thrombosis, infection, aneurysm formation and/or haemorrhage. 
Dialysis has been provided universally in Libya for about four decades through an expanding 
network of centres (n=39), almost exclusively as HD (241). The prevalence rate of ESKD 
treated by dialysis in Libya is among the highest in the Middle East region (624 pmp) (24\). 
Services for creation of AVF are, however, limited to only a few centres (15%) (241), 
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providing a significant challenge to achieving high rates of A VF use. Pre dialysis care is very 
limited because of weak PHC and a shortage ofnephrologists (241). Although all HD facilities 
are run by the Ministry of Health, there is a lack of national guidelines to facilitate uniform 
practice and promote efforts to improve services for the creation of AVF. There are no data 
available regarding the patterns of vascular access utilisation in Libya or risk factors associated 
with failure of permanent vascular access. We therefore aimed to conduct the first 
comprehensive study of vascular access utilisation in HD patients in Libya. 
7. 2. Methods 
A prospective observational study was undertaken of all adult (age 16 years or more) patients 
receiving HD treatment in 25 HD facilities (out of 39) in Libya from May 2009 to December 
2010. In Phase I we performed a cross-sectional study of 1712 patients (72% of total national 
HD population; n=2383). Patients who were away at the time of the field visit were excluded. 
Each HD facility was visited by the researchers and data regarding demographics, dialysis 
treatment and mean predialysis blood pressure readings from the last 3 HD sessions were 
collected. Data regarding vascular access utilisation and complications related to vascular 
access were collected mainly through interviews with patients. Other information including 
weight, height, blood pressure and haemoglobin values were collected from medical records 
and dialysis staff. 
In the second phase of the study patients who were using permanent vascular access in phase I 
were interviewed again after a minimum of I year. Data were not available for 142 patients due 
to loss to follow-up, transfer to a non-participating dialysis unit or patient refusal. Patients were 
asked about any incidents of vascular access related complications (thrombosis, infection and 
haemorrhage) and hospitalisation. All vascular access related incidents were recorded and 
included in the study even if the patient was transplanted or died afterwards. 
Ethical approval was granted for the research from the Ministry of Health. The project was 
approved by the Libyan National Committee for Bioethics and Bio-safety. Participants gave 
written informed consent. 
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Continuous variables are presented as median and interquartile range and groups were 
compared using a Mann-Whitney test. Categorical variables were compared using a Chi-square 
test. Data analysis was performed by using SPSS version 16.0. A p-value of <0.05 was 
regarded as significant. 
7. 3. Results 
At baseline the majority of patients (91.9%; n=1573) were using permanent vascular access 
(AVF or AVG) for maintenance HD. Of these, 76 patients were using an A VG (4.4% of the 
total HD population). Patient characteristics are summarised in Table 7. 1. Patients with A VF 
were more likely to be male and less likely to be diabetic that those with CVCs. Notably the 
median dialysis vintage was lO-fold higher in those with permanent vascular access. Patients 
with A VF had lower pre-dialysis blood pressure and higher haemoglobin than those with 
CVCs. The use of tunnelled catheters was limited to very few patients, most of them female 
and over half diabetic. 
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Table 7. 1: Patient characteristics by vascular access type 
Characteristics Types of Vascular Access 
Permanent Vascular Access CVC Tunnelled Total 
n=1573 (91.9) N=120 (7.1) Catheter N=1712 
N=19 (1.1) 
AVF N=1497 AVG 
(87.4) N=76 (4.4) 
Age (years) 49 (36-61) 50 (36-61) 52 (37-64) 44 (26-62) 49 (36-61) 
Male 869 (58) 40 (52.6) 69 (57.5) 7 (36.8) 985 (57.5) 
Female 628 (42) 36 (47.4) 51 (42.5) 12 (63.2) 727 (42.5) 
Duration of dialysis 3 (1-7) 4 (2-7) 0.3 (0.1-0.7) 3 (1-7) 3 (1-6) 
(years) 
White ethnicity 1304 (89.6) 66 (86.8) 100 (84) 16 (84.2) 1486 (89) 
Black ethnicity 151 (10.4) 10 (132) 19 (16) 3 (15.8) 183 (II) 
Current smoker 189 (134) 10 (13.3) 7 (6.5) I (5.3) 207 (12.9) 
Diabetic 440 (29.4) 28 (36.8) 55 (45.8) 10 (52.6) 533 (31.1) 
Predialysis systolic blood 145 (130-170) 160 (135-173) 150 (130-175) 160 (130-170) 150 (130-170) 
pressure (mmHg) 
Predialysis diastolic blood 81 (80-90) 90 (80-90) 90 (80-100) 85 (70-90) 85 (80-90) 
pressure (mmHg) 
Body Mass Index in 
Kg/m2 24 I (213-275) 23.3 (207-29.5) 24. 1(213-277) 20.8 (202-284) 24 I (212-276) 
Haemoglobin (g/dl) 10 (8.8-11.4) 9.8 (8.8-11.3) 8.6 (7.6-9.6) 10 (8-11.5) 9.9 (8.7-11.3) 
Data are median (interquartile range) or number (%) 
A VF= Arteriovenous fistula 
A VG= Arteriovenous graft 
eve = central venous catheter (non-tunnelled) 
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Upper arm permanent vascular access was more common than forearm overall but forearm 
vascular access was more common in males «0.001). (figure 7. I). 
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Figure 7. 1: Site of permanent vascular access according to gender 
Utilisation of vascular access at the start of dialysis showed a strikingly different pattern. Most 
patients had commenced HD using a temporary eve (91.8%) and only a small minority with 
an AVF (7.8%) or AVa (0.4%). None had started HD with a tunnelled catheter. Overall , 1448 
patients were admitted to hospital at the time of initiation of HD (87.1 %). Figure 7.2 describes 
the relationship between the type of vascular access used and duration of HD. Utilisation of 
A VF for HD increased progressively in those who passed the first year of HD treatment. 
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Figure 7. 2: The relationship between prevalence of type of vascular access used 
and dialysis vintage 
(TC=tunnelled catheter; CYC=temporary central venous catheter; A YG=arteriovenous graft; 
A YF=arteriovenous fi stula) 
The most common vascular access- related complication was thrombosis and this was reported 
by almost half of patients (46.7%). Moderate to large aneurysm transformation was observed in 
22.6% and was more common in males (P=0.003). History of infection was reported by 11.5% 
whi le moderate to severe haemorrhage was reported by 10.2%. (figure 7.3). 
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Figure 7. 3: Number of haemodialysis patients with permanent vascular access 
with a history of various types of vascular access related complications 
Of those reporting thrombosis, it had occurred once in 57.8%, twice in 24.6% and three or 
more times in 17.6%. (figure 7. 4). 
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Figure 7. 4: Frequency of previous thrombosis of permanent vascular access in 
haemodialysis patients 
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Factors potentially associated with a history of previous episodes of permanent vascular access 
thrombosis are shown in Table 7. 2. Patients with a history of vascular access thrombosis 
tended to be younger, more likely to be female, had a longer dialysis vintage, less likely to 
smoke, more likely to have upper arm vascular access and had lower predialysis blood 
pressures. 
Table 7. 2: Factors potentially associated with a history of permanent vascular 
access thrombosis 
Thrombosis No thrombosis 
1573 cases 
N=735 (46.7%) N= 838 (53.3%) 
Age (years) 46 (35-60) 50(37-61) 
Male 354 (48.2) 555 (66.2) 
Female 381 (5\.8) 283 (33.8) 
Duration of dialysis (years) 5 (2-9) 2 (1-4) 
White ethnicity 636 (89) 734 (89.6) 
Black ethnicity 76 (II) 85 (10.4) 
Current smoker 77(11.1) 122 (15.4) 
Forearm location 295 (40.1) 449 (53.6) 
Upper arm location 440 (59.9) 389 (46.4) 
Diabetic 211 (28.7) 257 (30.7) 
Predialysis systolic blood pressure (mmHg) 140 (130-161) 150 (130-170) 
Predialysis diastolic blood pressure (mmHg) 80 (80-90) 85 (80-90) 
Body Mass Index in Kg/m2 23.9 (21-27.5) 24.2 (21.5-27.6) 
Haemoglobin (gldl) 10 (8.9-11.4) 9.9 (8.7-11.4) 
Data are median (interquartile range) or number (%) 
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Of patients with penn anent vascular access, 24.4% reported an admission to hospital due to 
vascular access related complications during the year prior to interview. The proportion of 
female patients who reported hospitalisation was greater than males (28.8% vs. 21.3%; 
p<O.OOI). 
Of those with penn anent vascular access at baseline (n=1573), 142 were lost to follow-up. 
Thus 1431 (78.3%) were interviewed for a second time. Of these, 14.7% reported vascular 
access thrombosis during the one year study period. Thrombosis with infection was reported by 
4.9% and thrombosis after moderate to severe haemorrhage was reported by 2.2%. Thrombosis 
was more common in female patients (\ 8.1 % vs. 12.3%; p=O.OO I). Hospitalisation for vascular 
access related complications was reported by 3 I .4%. Factors potentially associated with 
incident vascular access thrombosis in I-year follow up period are shown in Table 7. 3. Those 
who developed thrombosis were more likely to be female or diabetic, have upper ann vascular 
access and lower predialysis blood pressures. 
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Table 7. 3: Factors potentially associated with incidence of permanent vascular 
access thrombosis (1-year follow up) 
Thrombosis No thrombosis 
1431 cases 
N=211 (14.7) N= 1220 (85.3) P value 
Age (years) 49 (35-62) 48 (36-61) 0.996 
Male 102 (48.3) 728 (59.7) 
0.001 
Female 109 (51.7) 492 (40.3) 
Duration of dialysis (years) 3 (1-7) 3 (1-7) 0.743 
White ethnicity 183 (90.1) 1059 (88.8) 
0.341 
Black ethnicity 27 (11.4) 133 (11.2) 
Current smoker 20 (10.8) 168(14.4) 0.111 
Forearm location 88 (41. 7) 593 (48.6) 
0.037 
Upper arm location 123 (58.3) 627 (51.4) 
Diabetic 86 (40.8) 361 (29.6) 0.001 
Predialysis systolic blood pressure 
140 (115-160) 150 (130-170) <0.001 
(mmHg) 
Predialysis diastolic blood pressure 
80 (70-90) 89 (80-90) <0.001 
(mmHg) 
Body Mass Index in Kglm2 23.6 (20.7-27.9) 24.2 (21.3-27.7) 0.486 
Haemoglobin (gldl) 9.6 (8.7- 10.9) 10 (8.8-1 1.4) 0.060 
Data are median (interquartile range) or number (%) 
7. 4. Discussion 
The majority of patients (91.8%) in our study had started their HD therapy by using a 
temporary eve. This is undesirable because eves are associated with several serious 
complications including inadequate blood flow, infection and central vein stenosis. Previous 
studies have found that late referral to a nephrologist is a major determinant of eve use at 
initiation of HD and is associated with poorer outcomes. The use of eves at the initiation of 
HD varies in different countries. In the United States almost two thirds of patients initiate HD 
with a temporary eve but lower rates were reported in Germany and Japan. In Egypt, only 
10.2% of patients had a fistula created before the start of dialysis and a temporary eve prior to 
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permanent access was used in 90% of patients (288). A report from a single dialysis unit in 
Casablanca showed that a temporary CVC was used to initiate HD in 86.3% (287). The high 
rate of temporary CVC use at the start of HD observed in our study reflects poor predialysis 
preparation and failure of the health care system to detect CKD before it reaches end-stage. 
Achieving a placement of permanent vascular access prior to initiation of HD in Libya will 
require improved screening programmes for CKD and the establishment of comprehensive 
primary care services as well as improved nephrology and surgical services. 
Despite the obstacles to achieving permanent vascular access in Libya, the majority of 
prevalent HD patients studied (91.9%) had a functioning A VF or AVG. Data from DOPPS III 
(2005-2007) from II countries showed wide variation in vascular access patterns among 
countries with a highest rate of AVF (91%) in Japan and a lowest rate of AVF (47%) in the 
United States. The high rate of permanent vascular access use in Libya likely reflects an 
element of selection since patients who are unable to obtain permanent vascular access are less 
likely to survive. Our observation that patients with permanent vascular access had a dialysis 
duration lO-fold that of patients with a CVC supports this conclusion but further prospective 
research is required to investigate outcomes among those initiating HD with a cve in Libya. 
On the other hand, the high utilisation of permanent vascular access reflects determination on 
the part of dialysis staff and patients to overcome considerable obstacles to achieve A VF or 
AVG formation, since the necessary surgical services are available in only 15% of centres 
(241). There is an urgent need to improve surgical services so that permanent vascular access 
can be more readily offered to all patients. Access to tunnelled dialysis catheters in extremely 
limited in Libya and they are therefore used by only a small minority. 
Patterns of complications related to permanent vascular access are similar to those reported 
from other countries, with thrombosis the most frequent. Gender differences in site and patency 
rates of permanent vascular access have been reported by several studies (31, 32, 91, 293, 294) 
and, similar to our study, many authors have observed that females are less likely than males to 
have their permanent vascular access placed in the forearm because they have smaller vessels 
than men (31, 37). Allon et al. reported that women were significantly less likely to have 
suitable vessels for construction of AVF, when objective preoperative sonographic criteria 
were used (37). Gender discrepancy was also reported by Miller et al. who reported that 
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successful A VF formation was less likely be achieved in women despite routine preoperative 
mapping and frequent interventions to salvage A VF that failed to develop (295). 
Diabetes has been identified as a risk factor for reduced utilization of A VF in affected patients 
(91, 148, 149,288,296). The health care financing adminstration in the United States reported 
that only 22% of diabetic patients receiving HD were using A VF, as compared with 30% of 
non-diabetic patients (297). There is controversy as to whether diabetes is an independent risk 
factor for reduced A VF use or is a marker for associated factors such as arteriosclerosis (298). 
Leapman et al. observed excess poor outcomes with A VF in elderly and diabetic patients and 
recommended that other vascular access devices be considered for these patients (299). 
Diabetes was found to have an association with cephalic arch stenosis which contributes to 
thrombosis (300). These observations are important because diabetes is the single most 
common cause of ESKD in many countries including Libya. Improved surveillance of fistula 
function in patients with diabetes may help to preserve vascular access function in this 
important subgroup. 
Our study revealed a remarkably high rate of hospitalisation related to vascular access. First, 
most patients had commenced HD using a temporary eve and most were hospitalised at the 
time of initiation of HD. Second, a quarter of HD patients with permanent vascular access as 
baseline reported a history of admission to hospital due to permanent vascular access related 
complications during the year preceding the interview. Third, during one year follow up 
approximately one third of HD patients were admitted to hospital with permanent vascular 
access related complications. Hospitalisation rates for vascular access related problems are also 
high in the United States (60, 87, 301). A report by the USRDS (2011) shows that admissions 
for vascular access related infection have fallen from 2005 to 2009 by 19 % while admissions 
for sepsis remained high at 108 per 1,000 patient years in 2009 (10). Thus improved provision 
and maintenance of vascular access could result in considerable reductions in hospitalisations 
with improved quality of life for patients and reduced cost to the healthcare system. 
Several limitations to our study should be conceded. The type and frequency of vascular access 
related complications were obtained mainly from patient histories because most of the vascular 
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access related complications were not documented in the medical records. Among prevalent 
patients dialysis vintage varied widely and there was an element of selection bias since only 
surviving patients could be included. One hundred and forty two patients were lost to follow up 
during the 12 month observation period and our data may therefore underestimate the 
incidence of vascular access related complications in the study population. 
7. 5. Conclusion 
Few patients in Libya initiate HD using a permanent vascular access, but most achieve it 
thereafter. Attempts to improve the predialysis preparation including creation of definitive 
vascular access will likely result in improved outcomes and reduce the need for admission to 
hospital. This will require improved provision of primary care as well as nephrology and 
surgical services. Monitoring of vascular access to identify those at risk of complications could 
improve longevity of vascular access and should initially be targeted at females and patients 
with diabetes. This research was conducted prior to the recent conflict in Libya, which likely 
has resulted in disruption of nephrology and surgical services. Re-establishment of these 
services and improved provision of definitive vascular access at more centres should be made a 
priority in the rebuilding of health care in Libya. 
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8. Determinants of survival in patients receiving 
dialysis in Libya 
8.1. Introduction 
Maintenance dialysis sustains life for more than one million patients throughout the world. 
Nevertheless survival on dialysis is dramatically reduced compared to the general population 
and is comparable to survival with many forms of cancer. Thus survival is arguably the most 
important outcome measure for assessing the overall quality of dialysis provision in a centre, 
region or nation. Previous studies have identified considerable variation in survival rates from 
different centres (39, 40, 302), influenced by the type of dialysis used (303, 304), demographic 
and social characteristics of dialysis patients (305, 306), provision of predialysis care and 
associated comorbidities such as diabetes, cardiovascular diseases, abnormal bone and mineral 
metabolism and malignancies (30, 40, 307). The observed variation also suggests that 
intervention is possible to improve survival. Practice guidelines have been developed to 
standardise the delivery of dialysis and promote best practice and have likely contributed to 
improvements in survival rates seen in Europe, Japan and the United States (308). 
In Libya, free access to state-funded dialysis has been available for four decades but data 
regarding outcomes are scarce. A renal registry has not yet been established to collect outcome 
data and }here are no nationally accepted clinical practice guidelines to promote best practice in 
dialysis care. We therefore aimed to investigate survival rates, determinants of survival and 
causes of death in Libya's dialysis population. 
8. 2. Methods 
This prospective observational cohort study included all patients treated at dialysis facilities in 
Libya (n=38/40) aged 16 years or more who had reached at least 90 days of dialysis during 
May 2009. One dialysis facility was excluded because it provided dialysis only to paediatric 
patients and another new facility because no patients had been treated for more than 90 days. 
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Large and medium capacity HD facilities were visited by the researchers in order to collect 
data. For small and remote facilities, data collection forms were posted to clinical supervisors 
who were requested to collect information about their patients. They were contacted frequently 
by phone to deal with any queries related to the required variables. Forms were returned within 
30 days. On enrolment, data collected included socio-demographic information, dialysis 
modality, body weight, height, history of diabetes, type of primary renal disease, haemoglobin 
concentration, history of previous renal transplantation and date of dialysis initiation. In 
addition, 1759 patients from 26 centres were interviewed regarding other potential risk factors 
for mortality. These included modes of presentation with ESKD, clinical history, predialysis 
systolic and diastolic blood pressure, delivered HD hours per week and results of biochemical 
tests. Planned onset of dialysis was defined as a history of predialysis medical care for 3 
months prior to the start of dialysis. Physical independency is defined as a normal physical 
performance without the need for aids or assistance. 
Survival was assessed after one year of follow-up. The outcome of all participants was 
recorded except for patients who received a renal transplant, transferred to another dialysis unit 
where a follow up could not be determined or recovered renal function. Patients who changed 
to another dialysis modality were included. Cause of death was recorded from the medical 
records of patients and grouped into 10 categories. "Unknown" was used when the cause of 
death could not be identified. 
Permission to conduct the study was granted by the Ministry of Health. Ethical approval for the 
research was obtained from the Libyan National Committee for Bioethics and Bio-safety. 
Patients each gave written informed consent. 
Continuous variables are presented as mean± SD if normally distributed or median and 
interquartile range if not. Groups were compared using a (-test or Mann-Whitney test. 
Categorical variables were compared using chi-square test. Factors associated with mortality in 
the univariate analyses were included in a multivariable binary logistic regression analysis to 
identify independent risk factors for mortality. The exact date of death was not available in 
many patients and Cox regression models could therefore not be employed. Data analysis was 
performed by using SPSS version 16.0 (SPSS, Inc., Chicago, IL, United States). A p-value of 
<0.05 was regarded as significant. 
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8. 3. Results 
A total of 2273 patients who had been on dialysis for at least 90 days in 38 dialysis centres 
were followed up for one year. The mean age was 48.7±15.5 years and 57.1% were males. The 
majority were receiving HO and only 26 were on PO (1.2%). Sixty-seven patients (3%) 
received a renal transplant and 46 patients were transferred to another dialysis unit where their 
follow up could not be confirmed. One patient recovered renal function after 2 years of HO. 
Thus 2159 patients were successfully followed up and included in the analysis of survival. At 
the end of the observation period the majority of patients (1697) were still receiving HO while 
only 4 patients had converted to PD. Four hundred and fifty eight patients died, giving a crude 
annual mortality rate of21.2% (HO: 448 of2133=21.0%; PO: 10 of26=38.5%). 
The highest mortality was observed in the age group 75-84 years (43.3%) whereas the best 
survival was in the age group 25-34 years (figure 8. I). The causes of death are shown in figure 
8. 2. By far the most common cause of death was cardiovascular disease (ischaemic heart 
disease 31%; cerebrovascular disease 16%) and infection was the second most common. The 
mortality rate in the Libya's 38 dialysis centres ranged trom 0% to 70%. A particularly high 
mortality rate of over 30% was observed in 7 centres (figure 8. 3). 
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Figure 8. 1: I-year survival (%) among patients who were alive after 90 days of 
dialysis and number of patients in each age group. 
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Figure 8. 3: 1- year mortality rates in Libya's 38 dialysis centres. Codes are 
random to anonymise data. 
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Baseline data are shown in Tables 8. I and 8. 2, grouped according to survival status at I year. 
Those who survived were younger, had longer duration of dialysis, lower predialysis systolic 
blood pressure, more time on HD each week, higher haemoglobin concentration and 
haematocrit, higher predialysis creatinine and lower predialysis urea. Patients who died were 
more likely to have had diabetes, past history of cerebrovascular accidents, on HD, be married, 
have had no higher education, be physically dependent, current smokers and have had 
unplanned initiation of dialysis. 
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Table 8. 1: Baseline data grouped according to survival status at 1 year. 
(Continuous variables) 
Outcome of dialysis patients 
Survived Died 
2159 P-value 
N=1701 N=458 
Number* Value Number* Value 
Age in years 1701 46 (34-59) 458 55.7 (46-66) 0.001 
Age at onset in years 1701 41 (28-55) 458 54 (42-63) 0.001 
Dialysis vintage in years 1701 3 (1-7) 458 2 (1-5) 0.001 
Body Mass Index (kg/m2) 1698 23.7 (20.8-27) 457 23.8 (21-27.6) 0.178 
Predialysis systolic blood 
1213 140 (130-170) 338 150 (130-170) 0.002 
pressure 
Predialysis diastolic blood 
1213 85 (80-90) 338 85 (80-90) 0.300 
pressure 
Haemodialysis hours per 
1167 9.98±2.3 330 9.55±2.4 0.003 
week 
Serum Albumin (g/dl) 413 4.4 (3.9-5) 151 3.6 (2.3-4.5) 0.001 
Haemoglobin level in g/dl 1701 9.9 (8.8-11.2) 458 9.3 (8.5-10.6) 0.001 
Haematocrit (%) 918 25.9 (22-31.9) 245 24.6 (21.8-30) 0.016 
Serum Ferritin (ng/mL) 143 83 (42-246) 45 64 (42-141) 0.446 
Serum <;:holesterol (mg/dl) 433 154 (126-184) 122 142 (120-174) 0.062 
Serum Phosphorus (mg/dl) 861 5.5 (4.3-6.8) 234 5.4 (4.2-6.7) 0.568 
Serum Calcium (mg/d\) 968 9 (8-9.8) 272 8.8 (7.9-9.6) 0.158 
Predialysis creatinine 
982 10.2 (8-12.4) 258 9.4 (7.3-11.7) 0.008 
(mg/dl) 
Predialysis urea (mg/dl) 1000 120 (85-154) 296 142 (86-170) 0.001 
*Number of patients with valid data for each variable 
Values are median (interquartile range) or mean± standard deviation 
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Table 8. 2: Baseline data grouped according to survival status at 1 year. 
(Categorical variables) 
Outcome of dialysis patients 
Survived Died 
P-value 
N=1701 N=458 
Number* Value (%) Number* Value (%) 
Male 1701 962(56.6) 458 271 (59.2) 0.171 
Married 1174 793 (67.5) 341 289 (84.8) 0.001 
White 1664 1465 (88) 446 379 (85) 0.091 
Higher education 1048 430(41) 300 90 (30) 0.001 
Physically dependent 1197 303 (25.3) 343 147 (42.9) 0.001 
Current smoker 1183 156 (13.2) 332 3 I (9.3) 0.034 
Diabetic 170J 437 (25.7) 458 223 (48.7) 0.001 
Previous cerebrovascular 1241 88 (7.1) 360 71 (19.7) 0.001 
accidents 
Haemodialysis 1701 1685 (99. I) 458 448 (97.8) 0.033 
Planned onset of dialysis 1204 79 (6.6) 347 40 (11.5) 0.002 
*Number of patients with valid data for each variable 
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Binary logistic regression analysis was used to identify independent risk factors for increased 
I-year mortality. Cases with missing variables were excluded, thus 1189 cases were included 
in this analysis. Independent variables used in the analysis were: age at onset (years), 
physically dependent, diabetes, HD hours per week and predialysis urea. Results are shown in 
Table 8. 3. 
Table 8. 3: Independent risk factors for increased I-year mortality in dialysis 
patients 
HR 95.0% CI P- value 
Age at onset (years) 1.037 1.027-1.047 <0.0001 
Physically dependent 1.818 1.333-2.480 <0.0001 
Diabetes 1.479 1.078-2.028 0.015 
Predialysis urea 1.004 1.001-1.007 0.002 
Hosmer and Lemeshow test for goodness of fit P- value =0.995; Nagelkerke R Squared=0.164 
8. 4. Discussion 
This stUdy is the first comprehensive assessment of survival in patients receiving dialysis in 
Libya. The crude annual mortality rate of 21.2% is similar to that reported in many other 
countries. A death rate of 26.4% was reported in the Saudi dialysis population (309) while in 
Jordan the rate was 20% (20). Afifi and Karim reported annual mortality of 11.7% in Egypt 
(286). In Syria, the three-year survival rate ranged from between 26% to 64% in different 
dialysis centres (310). A previous study in a single dialysis unit in Libya showed an overall 5-
year mortality rate of 51.4% (311) which was higher than the United States and the UK (312). 
The annual mortality rate in dialysis patients has declined in the United States but it is still high 
for certain groups, exceeding 20%. In Europe, it has been reported to be 19.8% (313) while in 
the UK it ranged from 14.6% to 18.4% in different regions (314). In Japan the annual death 
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rate has improved progressively (315, 316) and recently it has been less than 10% (174). Qatar 
has also reported a reduction in the annual mortality rate from II % in 2002 to 7% in 2006 (16). 
Despite the apparently favourable comparison with survival on dialysis in other countries, it 
should be noted that the median age of dialysis patients, an important determinant of survival, 
is substantially lower in Libya than in most developed nations. Thus survival on dialysis is low 
compared with many other countries. The reasons for this relatively poor survival require 
further investigation but it is likely that multiple factors are involved. Our observation that 
patient who died had lower median hours per week of dialysis and higher predialysis urea 
suggests that delivered dialysis dose may be one factor. The lower serum albumin and 
haemoglobin observed in those who died may reflect poorer nutrition and inadequate 
management of anaemia but both albumin and haemoglobin are negative acute phase reactants 
and may therefore be a marker of other disease processes that account for increased mortality. 
Higher predialysis systolic blood pressure in those who died may have contributed to deaths 
due to cardiovascular disease. Pre-existing medical conditions also increase the risk of 
mortality on dialysis. Physical dependency, diabetes and previous cerebrovascular events were 
more common in those who died and the former two factors were independent determinants of 
survival. Nevertheless, the prevalence of comorbid conditions was relatively low, apart from 
diabetes. Thus an excess of comorbid conditions is unlikely to explain the observed high 
mortality rate. 
The distribution of causes of death observed in our study was similar to that reported from 
most other countries (174, 314, 317). In common with almost all previous studies, 
cardiovascular and cerebrovascular disease accounted for the majority of deaths and infection 
was the second most common cause. On the other hand, our results revealed other causes of 
death which are not common in other countries such as anaemia! bleeding, malignant 
hypertension, uraemia and liver failure. Death due to anaemia or bleeding suggests a lack of 
adequate blood transfusion services as well as inadequate resources for the treatment of 
anaemia whereas death due to uraemia implies that some patients are severely under-dialysed. 
It is very likely that some of the deaths due to uraemia result from inadequate dialysis due to a 
lack of sufficient dialysis capacity in some areas. The observation that sever hypertension is the 
cause of death in a small number of patients implies that attention to optimising fluid volume 
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status and treatment of hypertension is inadequate in some centres. Finally, the deaths due to 
liver failure are likely to have resulted from the very high prevalence of hepatitis C virus 
infection (31 %) observed in dialysis patients in Libya. 
Our results show a very wide variation in annual mortality in different units in Libya. The 
crude mortality rate in 7 units was higher than 30%. It is unlikely that this variation could be 
attributed wholly to variation in patient demographics or comorbidity profile and it therefore 
probably reflects variation in practices related to dialysis delivery. The observed variation 
suggests opportunities for improving outcomes by identifying best practice and standardisation 
of practice across all centres. At present there are no nationally accepted guidelines for dialysis 
in Libya and no renal registry to monitor outcomes. Moreover, many dialysis centres lack 
resources to monitor biochemical indicators and adequate monitoring of dialysis adequacy is 
achieved in only a minority of patients (241). The development of clinical guidelines for 
dialysis in Libya or the adoption of international guidelines should be an urgent priority to 
improve survival and the establishment ofa renal registry should be an important medium-term 
goal. Improved monitoring and treatment of high risk patients may also help to improve 
survival and our results indicate that efforts should focus on high-risk groups including the 
elderly, those who are physically dependent and those with diabetes. 
Our study has several limitations. A small proportion of patients were lost to follow-up and it is 
likely that some of these died, implying that our observed annual mortality rate may be slightly 
lower than the true mortality rate. Medical records were unfortunately incomplete in many 
cases and we therefore had to rely on patient histories for information regarding past medical 
history (although the ability to independently corroborate historical data by direct patient 
interaction may be seen as a strength). Thirdly, the causes of death could not be accurately 
confirmed as many deaths occurred outside the centre and/or the local hospital. Finally, the 
short follow-up period enabled us to prospectively determine the crude I-year mortality rate 
but a longer study period would provide a more comprehensive description of survival trends. 
8. 5. Conclusion 
Patients receiving dialysis in Libya have a crude I-year mortality rate similar to most 
developed countries but the mean age of the dialysis popUlation is much lower and this 
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outcome is thus relatively poor. As in most countries, cardiovascular disease and infection 
were the most common causes of death. Variation in mortality rates between different centres 
suggests that survival could be improved by promoting standardisation of best practise. 
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9. Discussion, conclusion, limitations, implication 
and future work 
9.1. Discussion 
We aimed to undertake a comprehensive description to the epidemiology of dialysis-treated 
ESKD in Libya and assess the provision of dialysis services in the country. Libya is a low 
populated medium developed country and is the 4th largest country in Africa. Most people live 
in the North of the country but there are many small communities scattered throughout the 
country which represent a challenge to health care authorities to deliver high quality services to 
minorities in remote places especially in the Sahara. Large distances between cities create 
difficulties in terms of providing necessary staff and regular supplies as well as maintenance 
services (318-320). 
Initially, we assessed the feasibility of using information from the Ministry of Health and the 
national drug and medical supplies company. Therefore, we contacted them to obtain an 
updated list of the functioning maintenance dialysis facilities in the country as well as the 
number of patients receiving treatment in each facility. We were surprised to discover that this 
information was not held by the Ministry. Moreover, there was no renal registry or any 
alternative body monitoring the delivery of dialysis treatment. We found that there were no 
clear means of communication between the Ministry of Health and dialysis centres or between 
dialysis centres themselves. There were no contact details available for most dialysis facilities. 
Therefore, we created the first comprehensive list of dialysis facilities and their contact details 
by contacting each hospital in the country to enquire about provision of dialysis services either 
within the hospital or as a satellite unit supervised by the hospital. In addition, we tracked the 
delivery of dialysis consumables from the main stores to the distribution points. Finally, we 
identified 40 functioning maintenance dialysis facilities by May 2009 (one of them serving 
children only). We established communications with the clinical managers in each facility and 
contacted them by mobile telephone. This initial phase of the study therefore identified a major 
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weakness in the provision of dialysis in Libya, namely a lack of central co-ordination of 
services and monitoring of quality or outcomes. It is vital that this shortcoming is overcome if 
the quality of dialysis provision is to be improved. Establishing the first comprehensive list of 
facilities and their contact details through this study will hopefully be the first step in this 
improvement. 
After initial assessment through field visits to 5 dialysis facilities, we realised that we would 
have to collect the required data in person rather than depending on local dialysis staff to 
provide us with information about each dialysis patient. This decision was taken to ensure the 
validity and consistency of information and also because we found that dialysis staff in the 
large capacity facilities were very busy and could not find time to collect and document the 
required information. Another important consideration was the observed low quality of 
medical records, which were often incomplete; necessitating the use of alternative sources such 
as patient interviews, biochemical results folders and staff interviews (we observed that many 
dialysis nurses have good knowledge of their chronic dialysis patients). Therefore we set a 
time table and arranged visits with the clinical managers of 28 facilities. We travelled 
throughout the country and visited all medium and large size maintenance dialysis facilities 
(n=28) where we interviewed the clinical managers as well as all patients. We relied on 
telephone phone interview for the remaining small facilities to collect the required information 
about the dialysis provision and sent data collection forms to be completed by the staff in these 
facilities. 
Our results showed that maintenance dialysis was provided in all regions of Libya. Services 
were freely accessible for all nationals as well as residents. Non- residents were charged for 
treatment. Maintenance dialysis was provided only by the public sector. All supplies and 
consumables were imported from overseas through a single provider (Ministry of Health) who 
contracted with different producers. The supplies and consumables were unloaded in a central 
store in Tripoli then distributed to 3 main regional stores for distribution. All facilities provided 
HD but only three provided CAPD to a minority of patients. Large capacity, purpose built 
facilities were located in the 2 main cities, Tripoli and Benghazi. However, most dialysis 
facilities in the country were in buildings originally built for a different purpose. To respond to 
increasing demand on dialysis, almost all dialysis facilities has undergone expansion by fitting 
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in more HD stations at the expense of space. Work load varied widely where some dialysis 
facilities were working to maximum capacity while others run only a few sessions per week. 
This practice reflects lack of integration in health care planning. There were a considerable 
number of HD machines in the facilities but many of them were non-functioning. Weak 
technical support particularly in remote areas resulted in an accumulation of non functioning 
HD machines in each facility which is a waste of health care resources. For example, 28% of 
HD machines in the Southern region of the country were non-functioning. All dialysis facilities 
reported intermittent shortage of most types of medication, supplies and reagents needed for 
laboratory testing. Managers solve these problems by a variety of approaches including 
borrowing supplies from other dialysis facilities, temporarily reducing the frequency of 
dialysis, asking patients to buy the needed medication or laboratory testing on their own 
expenses from the private sector. Interrupted supplies reduce the quality the services and reflect 
suboptimal organisation of the health care system. 
We also observed that the number of expert nephrologists was extremely low and most patients 
were managed by internists and untrained medical graduates. The deficiency of expert 
nephrologists in the country reflects defective planning of graduate educational training. We 
observed that the ongoing patient management was mostly delivered by nurses. In the Southern 
region, there were two centres completely run by nurses. 
Furthermore, our study showed that there are no national dialysis practice guidelines in use. 
Only a few practitioners were familiar with the NKF/KDOQI guidelines and they reported that 
they could not apply most of them due to local constricts such as interruption of supplies and 
medication. Lack of clinical practice guidelines, deficient training and lack of auditing in Libya 
have resulted in variable approaches to dialysis patient management. We observed that the 
majority of practitioners in dialysis centres relied on clinical monitoring and monthly pre-
dialysis urea concentration measurements which are an unreliable measure of dialysis 
adequacy. The use ofthe most widely accepted measure of dialysis adequacy Ktlv was limited 
to small numbers of patients, despite capacity for online measurement of Ktlv being available 
in most HD machine types used in Libya. The approach to biochemical assessment also varied 
widely where a number of facilities were not monitoring serum ferritin and total iron binding 
capacity, serum calcium and phosphorus, serum albumin and parathyroid hormone either due 
125 
to lack of faciliti es and/or lack of knowledge. We also observed a severe shortage of dieticians 
and social workers as well as educational materials in most facilities. 
Other findings were that there were no water quality analysis reports in any dialysis facilities . 
In quarter of dialysis facilities, water samples for biological quality were collected during the 
year prior to the study but results were never reported. Furthermore, we found that the large 
amount of waste generated from daily dialysis activities was mostly treated by dumping or 
open air incineration alongside the domestic waste, creating a significant environmental 
hazard. (figure 9.1) 
Figure 9. 1: waste generated from daily dialysis activities collected in the 
backyard of a dialysis centre (Tripoli) 
.' 
In the epidemiological study, we collected baseline information on all adults who were 
receiving maintenance dialysis in Libya. We could not access information about the cases of 
ESKD who were transplanted or died before being referred to maintenance dialysis facilities 
because of the lack of a registry for such cases. Therefore, the incidence of ESKD we observed 
probably underestimates the true incidence of ESKD. We interviewed all patients who gave 
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consent, n= 1766 patients (73.1 % of all adult dialysis- treated patients in Libya) from 28 
dialysis facilities and we collected additional information from their medical records and 
treating staff. We applied a structured questionnaire which enabled us to gather a wide range of 
epidemiological and medical information as well as information about specific aspects in 
dialysis including HBY and/or HCY infection and vascular access. We gathered data from the 
small facilities by sending data collection forms for completion by staff and added them to the 
information collected through field visits. We ultimately managed to determine the prevalence 
and causes ofESKD in adult patients receiving maintenance dialysis in Libya in August 2009. 
At the same time, we established a prospective collection of information about all new patients 
who started dialysis from September 2009 to August 2010 in order to determine the incidence 
of dialysis-treated ESKD in Libya. 
Our results showed a remarkably higher prevalence of ESKD (624 pmp) than the rates 
observed in other countries in the Middle East region despite racial, socioeconomic and 
environmental similarities. Most prevalent patients were of economically active age with peak 
prevalence rate at 55-64 years. The diagnosis of primary kidney disease was clinical in most 
cases. Reasons for reliance on clinical rather than histological diagnoses include lack of 
guidelines, limited resources and pathology services and late presentation of patients with 
ESKD. Accurate diagnoses supported by histopathology reports were found in only a few 
patients. Diabetes was the most important cause of ESKD affecting 41.1 % of those who were 
50 years or more. The high prevalence of diabetes in the general population could be an 
import!U1t reason for high prevalence of ESKD observed in Libya, although the prevalence of 
diabetes is even higher in other Middle Eastern countries. Weak PHC and poor management of 
diabetes may contribute to the high risk for acquiring ESKD. Another interesting observation 
was the high proportion of ESKD caused by congenital and hereditary diseases in addition to 
polycystic kidney disease. The burden of these diseases could be reduced by genetic 
counselling and early management. However, weak preventive services in Libya and limited 
access to genetic counselling likely contribute to the observed high prevalence rate. 
We found a high incidence rate for ESKD (282 pmp) during our I-year follow up study. The 
number of new patients starting dialysis in one year was 45% of the prevalent number at 
baseline. This rate is among the highest in the world, only slightly lower than in Japan (287 
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pmp) despite a substantially lower median age for the general population in Libya. Moreover, 
our incidence rate was approximately double the rate reported from neighbouring Tunisia 
despite cultural and economic similarities between the countries. Our results also showed 
substantial differences between regions, with the highest incidence rate of 617 pmp observed in 
the South of Libya. The Southern region is the lowest populated area in the country and is the 
most socially and economically deprived region. It is also inhibited by a mix of people 
originating from different tribes. Racial disparities and social deprivation have been described 
as a risk factor for ESKD due to poverty, malnutrition, low educational levels, exposure to 
heavy metals and limited access to healthcare (321, 322). 
While assessing the provision of dialysis services in Libya, we observed that staff were 
applying variable practices to control nosocomial transmission of infection. Again, there were 
no guidelines to direct infection control measures. Nevertheless, sero-positive patients were 
dialysed on dedicated machines either in an isolation area or alongside sero-negative patients if 
space did not allow isolation. There were no previous reports about the prevalence, incidence 
and risk factors of HBV and/or HCV infections in the HD population of Libya. Therefore, in 
this part of the study, we focused on these infections. We included all adult patients receiving 
maintenance HD during May 2009 in all centres over the country (n=2382) and excluded 
CAPO-treated patients. We found that the overall prevalence ofHBV and/or HCV infections in 
HD population was 34.9%. However, the prevalence of HBV infection was similar to the 
general population of Libya despite our previous observation that HBV vaccination was 
a d m i n i s ~ r e d d in only 26% of dialysis centres. On the other hand, the prevalence of anti-HCV 
antibodies observed in patients receiving HD (31.1%) was remarkably high and is 
approximately 25 times higher than in the general population. Additionally, we observed that 
sero-positive patients had a longer time on dialysis and more previous blood transfusions 
which were highly suggestive of nosocomial transmission. Moreover, we observed that the 
prevalence of HBV±HCV infection varied widely between HD centres from 0% to 75.9%, 
implying that variable infection control measures contributes to variable rates of nosocomial 
infection. 
To determine the incidence of new HBV and/or HCV infections during I year, we followed up 
all previously interviewed sero-negative HD patients. Our results revealed an incidence of 
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sero-conversion of 7.7% during 1 year (7.1% HCV; 0.6% HBV). The rate of new HCV 
infections was more than rates reported in dialysis patients in many other countries. Wide 
variation in rates of newly acquired infections was observed between dialysis centres. All new 
HBV cases were referred from centres already treating HBV infected patients, suggesting cross 
infection between patients in the same dialysis centre. New HCV infections were reported in 
most centres but the rate of H CV sero-conversion varied widely from 1.5% to 31 %. This result 
might reflect variation in nosocomial control polices between centres as well as anaemia 
management and quality of blood screening procedures. Risk factors significantly associated 
with sero-conversion included; duration of dialysis, history of previous renal transplant and 
history of receiving HD in another centre in Libya. 
We explored the patterns of vascular access in patients receiving maintenance HD in Libya by 
analysing information about 1712 HD patients who were interviewed in 25 HD facilities. Our 
results showed that the majority of HD patients were using permanent vascular access in the 
form of A VF. A VG use was very limited to only 4.4% of total number of patients included in 
this part of the study. High achievement of AVF use was found despite our previous 
observation that only 15% of dialysis facilities in Libya were providing permanent vascular 
access services. Nevertheless, our results showed that most HD patients had commenced their 
treatment via a temporary CVC which reflects poor predialysis preparation and inability of the 
health care system to detect cases of CKD early and refer them for management in a specialist 
service when appropriate. The problem is further exacerbated by limited access to vascular 
surgery -resulting from shortage of trained surgeons in this field as well as a shortage of 
radiological equipment needed for assessment and vascular mapping. Our results show that 
permanent vascular access was more likely to be placed in the forearm in males as compared to 
females. Results also showed that the thrombosis rate of both forearm and upper arm fistula 
was less in males as compared to females. 
We further assessed outcomes related to vascular access in I-year follow up study. All patients 
who were using permanent vascular access for dialysis at the time of the first interview were 
included. Results showed that the incidence of permanent VA thrombosis was 14.7% and was 
significantly more common among female patients. Hospitalisation for vascular access related 
complications was reported by 31.4% during the I-year period. 
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The final step in our study was to detennine the outcome of all patients who were receiving 
maintenance dialysis during May 2009 after monitoring them for I-year period. Our results 
showed that the annual crude mortality rate (21.2%) was within the range reported in many 
developed countries but the mean age of the dialysis population in Libya was approximately 2 
decades lower than these countries and the survival rate is therefore relatively poor. Patient 
characteristics that were identified by binary logistic regression analysis as independent 
detenninants of increased mortality included; age at onset of dialysis, physical dependency, 
diabetes and elevated predialysis urea. 
The unsatisfactory survival rate on dialysis could be explained by multiple factors including 
lack of training, auditing and communication between centres, shortage of qualified 
nephrologists and deficient monitoring of the biochemical indicators. We observed that dialysis 
practices in Libya were outdated in most facilities and inherited unsatisfactory practices were 
common. The suboptimal monitoring of dialysis patients was reflected by high median blood 
pressure values, low time on HD per week, low haemoglobin and haematocrit concentrations 
and low serum albumin concentration. Our results showed that there was large variation in 
mortality rates between different centres with annual mortality rates reaching 70% in a few 
centres. 
9.2. Conclusion 
ESKD in Libya is a major health problem where the incidence rate is among the highest in the 
world. Despite rapid expansion of dialysis services throughout the country, our study has 
identified that many aspects of dialysis provision are suboptimal and that outcomes are 
relatively poor. We have identified several major challenges to improving the quality of 
dialysis provision including lack of dialysis practice guidelines, absence of auditing and quality 
control and limited access to kidney transplantation. As Libya reorganises its health services in 
the post-conflict period it is hoped that this study will be the first step in establishing a renal 
registry and that the areas of concern highlighted will prompt the implementation of national 
clinical practice guidelines for dialysis. 
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9. 3. Limitations 
While this study has provided the first nationwide description of the epidemiology and 
treatment of dialysis- treated ESKD in adult population of Libya, there were a number of 
limitations that should be conceded. Researchers faced difficulties in collecting data because 
the medical records maintained by most dialysis facilities included only details of dialysis 
treatments. Information related to past medical history, diagnosis of primary kidney disease, 
co-morbidities, complications and hospitalisations as well as biochemical investigations was 
generally held in hospital inpatient records. Thus researchers frequently were forced to use 
other sources such as patients and staff interviews as well as collecting information from 
hospital archives. When assessing vascular access-related complications we mostly relied on 
information obtained from patients and staff rather than medical or laboratory reports. Cause of 
death was also often obtained from the staff when not documented in the medical records. 
We could not obtain detailed data for the 35 patients who were receiving CAPO in Libya 
because of deficient medical records which could not be overcome by interviewing patients as 
these patients attend the dialysis facilities only once monthly. 
Because of time, resource and transport constrains we could not visit 12 small capacity dialysis 
facilities. We collected information through pre-prepared data collection forms and frequent 
phone calls. Most of these facilities are in remote and deprived areas and are among the 
dialysis facilities with poorest outcomes. Despite observing clear ethnic variation in the 
incidenci and prevalence of ESKD, we could not determine exact rates in minority populations 
in Libya as the information about ethnic distribution of the general population is not 
documented in the national statistics. Reporting HBV and/or HCV infections and 
seroconversion was based on serological testing which was done in local laboratories and it is 
likely that there was some variation in the quality of testing. Testing for HCV relied on a third 
generation ELISA to detect anti-HCV antibodies and was recorded in each patient's medical 
record but confirmation or genotyping with PCR was not available. 
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9. 4. Implications 
This study has several important implications for health care policy-makers and managers of 
dialysis facilities. Despite adequate funding for dialysis services and rapid expansion to meet 
the population's needs, we have identified numerous severe deficiencies in the current system: 
• The healthcare service currently does not have adequate systems in place to detect and 
treat CKD in its early stages. Investing in primary preventive services to reduce the 
incidence of ESKD is cost-effective because of the high cost of dialysis and 
transplantation. Common approaches include community based health education 
programmes and equipping PHC services to identify patients with CKD and treat 
them at an early stage. Clear referral guidelines will promote timely referral for 
dialysis preparation and reduce the number of unplanned dialysis initiations. 
• We have observed wide variations in practice as well as outcomes between dialysis 
facilities. The development and implementation of dialysis practice guidelines will 
standardise best practice and improve the quality of dialysis provision. 
• The establishment of a national renal registry and standardisation of medical records 
should be regarded as an urgent priority. Analysis of data returns acts as a valuable 
feedback tool for patients, staff and providers in dialysis facilities. Moreover, it yields 
longitudinal descriptions of ESKD trends as well as treatment and assists national and 
international comparisons. 
9. 5. Future work 
Our findings have highlighted the need for more studies in this field because it generated 
several unanswered questions, including; 
• ESKD usually represents the "tip of the iceberg" of CKD in a community. Therefore, 
population-based studies are required to describe the extent of CKD in Libya to plan 
preventive and therapeutic services for affected people. 
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• The contribution of congenital and hereditary diseases to incidence and prevalence of 
ESKD reported in this study is relatively high. An investigation of modes of 
inheritance and the role of consanguity might help in planning counselling services. 
• We have reported a very high prevalence and incidence of HeV infection in dialysis 
facilities. This should prompt an urgent detailed assessment of infection control 
procedures and implementation of best practice in all centres. 
• Further studies are needed to investigate practices relating to the disposal of dialysis-
related medical waste to improve safe practice and reduce the impact on the 
environment. 
• Our finding that no chemical or biological monitoring of dialysis water quality was 
reported to dialysis facilities warrants prompt investigation. 
• Providing maintenance dialysis is a multidisciplinary task. We reported suboptimal 
staffing including; shortage of trained nephrologists, social workers, dieticians and 
vascular access surgeons and coordinators. More studies are needed to explore the 
obstacles to providing necessary staffing. 
• Fortunately, our second round of data collection ended one month before the 
revolution and associated war in Libya. The impact of the conflict on dialysis 
provision and outcomes should now be investigated. 
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Dialysis Centre Questionnaire 
o Visit o Phone 
Date.............................. Location of dialysis centre oinside a hospital o Free standing 
Centre name .......... , .......................... City ............................... Tel .............................. . 
Centre start date ................................................. Type of dialysis provided ....................... . 
Number of dialysis rooms.......... ... ... ... ...... ............ Number of all stations ........................... . 
Number of working stations ................................. Working days/week .............................. . 
Total number of patients ...................... , ............... Number ofCAPD patients ........................ . 
Minimal age of patients ..................................... Maximum age of patients .......................... . 
Presence of nephrology clinic oYes, in unit oYes, in hospital oNo 
Frequency of patient monitoring by a nephrologists HD .............................. PD ..................... '" 
Dialysis adequacy monitoring oNo oYes Type ................................ , ......... Frequency ........ . 
Application of dialysis practice guidelines oYes oNo If yes, type 
Time on HD for registered patients ................................. Frequency/week ............................ . 
Number of junior nephrologists ........... Number of senior nephrologists ...... Number of nurses ..... . 
Staffing 
Number of 
Number of junior 
Number senior 
Working nephrologists 
of nephrologists 
shifts 
patients Present On call Present 
-Morning 
Afternoon 
Evening 
Isolation of infected cases oYes oSome oNo 
Type of isolation 0 Group oindividual 
Isolation for septic patients oYes oSome oNo 
Hand wash facility in each room oYes oSome oNo 
Hand disinfection oYes oSome oNo 
Use of gloves oYes oSome oNo 
Machine disinfection oYes oNo 
163 
On 
call 
Number Number 
Number of 
of dialysis of social 
technicians 
nurses workers 
Method of waste disposal .......................... . 
Sharps separation ................. . 
Dialyser reuse DYes oNo 
Availability of dietician oNo DIn unit DIn hospital 
Number of patients waiting for HD ................ . 
Availability of pharmacy DYes oNo 
Availability of Medicines DYes oSome oNo 
Availability of Eperax DYes oSome 0 No 
Availability ofIV Iron DYes oSome 0 No 
Patient education DYes oSome 0 No 
Provision of vascular access surgery 
Water source ......................... . 
Water treatment DYes oNo 
Water quality test DYes oNo 
Biological DYes oNo Chemical DYes oNo 
DYes, in unit 
Frequency 
DYes, In hospital 
Frequency of viral screen testing ............................................................... . 
Availability of laboratory investigations in the centre 
Availability of Frequency Availability of Frequency Availability of Frequency 
laboratory laboratory laboratory 
investigations investigations investigations 
Haemoglobin Triglycerides Phosphorus 
Haematocrit Cholesterol Total proteins 
-
Serum Ferritin LDL PTH 
Fasting blood Liver Function Ktlv 
sugar Tests 
HbAlc Electrolytes Serum Albumin 
TIBC Uric Acid Predialysis urea 
Serum Iron Calcium Post dialysis urea 
164 
oNo 
Dialysis Patient Questionnaire 
10 ...... ... ...... ......... ............... .... Date... ... ... ................ ... ..... Centre .................................... . 
File number. ....................... D.O.B................ Sex......................... Nationality ..................................... . 
Ethnicity DWhite DBlack Marital status ....................... Number of children ........................ . 
Level of education ........................... Occupation ........................ Working at present DYes DNo 
Independent DYes DPartially DNo Cause of dependency 
H/O smoking DYes DNo Years of smoking ........................... Smoker now DYes DNo 
Presence of pre dialysis health problems... ..... ........ .............. ..................... Types of pre dialysis health 
problems .......................................................................................................................................................... . 
Duration in years ............................................................................................................................................. . 
Mode oftreatment. .................................................................................. Weight. ........... Height. ................. . 
Onset ofESRD DSudden DGradual DPlanned (fistula prepared) 
Presenting symptoms ..................................................................................................... . 
H/O admission at onset... ... ... ... ................ Duration ........................................................................... . 
Cause ofESKD ................................................................................................................ . 
Family H/O ESKD DYes DNo 
Number of relatives ....................................... Relationships ............................................................ . 
Renal biopsy taken DYes DNo Histopathology result ..................................................... . 
Date of 1'1 dialysis Change in modality DYes DNo 
Nephrology follow up DYes DNo Dlrregular DRegular at ............... . 
Rounds at aialysis centre DRoutine DOn demand DNo 
Frequency of laboratory investigation .............................................................................. . 
H/O vaccination DYes DNo Types of vaccine used ............................................................... . 
Blood transfusion DYes DNo Frequency ........................................................ . 
Vascular access site .................................................................................................................................. . 
Type of vascular access D Native tistula DGraft DPermanent catheter DTemporary C 
DCVC H/O vascular access block DYes DNo 
Frequency ................................................ . 
H/O vascular access complications Dlnfection DAneurysm DBleeding 
H/O HD abroad .................. Name of country ....................................................................... . 
H/O HD in other centre in Libya ..................................................................................... . 
165 
HD sessions per week ............................................. HD/hrs per each session ...................................... . 
H/O renal transplant DYes DNo 
Pre dialysis BP ................ .................... .1 ............................................. .. .1 ....................................... . 
Post dialysis BP ........................... .......... .1 .......................................... ..... .1 ..................................... . 
Viral infection DYes oNo Time diagnosed oPredialysis oPost dialysis 
Type of virus DHIV oHBV oHCV 
H/O hospitalisation after HD: Number 
Duration ......................................................................................................................... . 
Causes ................................................................................................................................................. . 
HID hospitalisation during the previous year: Number 
Duration ..................................................................................................................... . 
Causes ................................................................................................................................................ . 
Medication taken by the patient at present 
Eprax DYes oNo 
IV Iron DYes oNo 
Other. .............................................................................................................................................................. . 
Results of available recent laboratory test 
Test Value Test Value Test Value 
Haemoglobin Haematocrit Triglycerides 
Serum Total lipids Total 
Albumin proteins 
HbAlc Cholesterol PTH 
-
Serum Iron LDL Uric Acid 
Serum Alanine Creatinine 
Ferritin aminotransferase 
TIBC Aspartate Predialysis 
aminotransferase urea 
Fasting blood Alkaline Post dialysis 
sugar Phosphatise urea 
Phosphorus Calcium Other 
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